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On cross section, nwst sizable tunwrs reveal three regions that differ in their blood supply
and therefore their oxygen content. At the tunwr's core, the tissue is essentially dead be
cause ofa Inck ofoxygen, which is shown above as the /igh/-colored dots. The dark dots
represent accumulations ofa radiosensitizing drug that accumulates even in low-oxygen
regions oftumors, making the cells more vulnerable to killing by radiation therapy. See
"The Cells We're After," page 22.
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Catastrophic occurrences add to the burden on mental
health services, as do high-ri sk members of populations,
Diagnosing and assessing prevalence of mental illness is
now easier, thanks to a psychiatric interview that can be
admini stered by trained laypersons.
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Kinesin: A New Cellular Motor
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This newly discovered " motor" protein enables cells to
rapidly transport substances from one place to another,
A researcher in the Department of Cell Biology and
Physiology uses an enhanced video system that demon
strates this movement along the cell's lnicroskeleton,
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Transplanting Lire
Liver, heart and long-bone transplants join the well
established kidney transplant program at the medical
center, In the offing are heart-lung transplants, and a
revival of human heart valve transplants is underway.
On The Cover:
Families uprooted by floods or other
disasters become persons who may need
mental health services. Thanks to a diag
nostic survey developed in parI by wu.
researchers, "psychialric Iriage" can be
performed by trai ned laypersons.
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Like all surgical procedures, organ transplants would be
impossible if not for the skill of the anesthesiologi st.
Some " internists of the operating room" describe the
special problems that they surmount to make these major
surgical endeavors successful,
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The Cells We're After

An older drug's newer analog can help improve radiation
therapy's ability to destroy cancer cells, Washington
University is one of the North American medical centers
where the drug SR-2508 will undergo Phase III testing.
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S. Sen. Thomas F
Eagleton, D-Mo.,
• delivered a keynote
speech at ceremonies designat
ing Washington University in
SI. Louis as an Alzheimer's
Disease Research Center
(ADRC). Washington Univer
sity is one of ten institutions
that have received five-year
funding from the National
Institute on Aging (NIA) to
study Alzheimer's Disease.
Eagleton was instrumental
in establishing the National
Institute on Aging and has
worked to obtain federal fund
ing for health care research,
particularly through the
National Institutes of Health.
The center will receive more
than $3.7 million in NIA fund
ing over the next five years.
A neurological disorder with
no known cause or cure,
Alzheimer's Disease affects an
estimated two million Ameri
cans and is the most common
cause of intellectual impair
ment and institutionalization
among the elderly.
The Washington University
ADRC will take an interdisci
plinary approach to research
on Alzheimer's disease and
related disorders. Established
investigators will conduct a
wide range of studies, examin
ing behavioral as well as bio
medical aspects of the disease.
Researchers will compare the
healthy aging process with
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that of Alzheimer's-induced
dementia; search for neurobio
logical factors that could be
associated with the disease;
explore changes in the aging
brain that may contribute
to Alzheimer's disease; and
investigate the disease's im
pact on the family and the
community.
The ADRC also will train
scientists and health care
professionals, and provide the
public with information on
research advances.
The center's director,
Leonard Berg, M.D., is profes
sor of clinical neurology at the
School of Medicine. He is pro
gram director of the medical
school's Memory and Aging
Project, a long-term study of
intellectual function in people
aged 65 and older, and a physi
cian at Barnes, Children's and
Jewish hospitals.
For further information
about the new center, call
ADRC coordinator Sandy
Venegoni at 362-2881.

." n

1)I)oinh'd
Pro

'O.;;t

Maxwell Cowan,
vice president of
The Salk Institute
for Biological Studies in La
Jolla, Calif., has been ap
pointed provost and executive
vice chancellor effective Au
gust 1986, Chancellor William
H. Danforth has announced .
Cowan returns to Washing
ton University where he pre
viously served as head of the
Department of Anatomy and

W. Maxwell Cowan
Neurobiology from 1968 to
1980 and director of the uni
versity's Division of Biology
and Biomedical Sciences from
1975 to 1980.
A co-founder of the Division
of Biology and Biomedical Sci
ences, Cowan led a pioneering
effort to bridge the gap be
tween the faculties of arts and
sciences and of medicine, espe
cially in the graduate training
of young biological scientists.
The division involves several
of the university'S scientific de
partments - biology, anatomy
and neurobiology, biological
chemistry, celJ biology and
physiology, genetics, micro
biology and immunology,
pathology, and pharmacology.
The program enables young
scientists in training to move
freely among the disciplines in
areas as varied as population
biology, ecology, plant biology,
molecular and cellular biology,
and neural sciences.
Cowan's association with
the university began in 1965
when, on sabbatical from
Oxford University, he was a
visiting associate professor
of anatomy in the School
of Medicine.

After spending two years
at the University of Wisconsin ,
he returned in 1968 as profes
sor and head of the Depart
ment of Anatomy. He also held
a joint position in biomedical
engineering in the Department
of Electrical Engineering and,
in 1978, was appointed Edison
Professor of Neurobiology.
In 1978, Cowan was asked
to serve as a non-resident fel 
low of The Salk Institute for
Biological Studies and, in 1980,
moved to La Jolla as a research
professor at the Institute and
as a senior investigator of the
Clayton Foundation for Re
search. In 1982, he was named
vice president of the Institute
and director of the Weingart
Laboratory for Developmental
Neurobiology. He also has
served as an adjunct professor
in the departments of biology
and neurosciences at the
University of CaliforniaSan Diego.
A native of Johannesburg,
South Africa, Cowan received
his undergraduate degree from
Witwatersrand University,
Johannesburg, and his graduate
degrees from Oxford Univer
sity, England, on whose faculty
he served from 1953 to 1966.
Cowan, who also is the
author of many scientific pub
lications, currently serves as
editor-in-chief of the lournal
ofNeuroscience and editor of
the Annunl. Reviews ofNeuro
science. For II years, he was
managing editor of the lournal
ofComparative Neurology. He
also serves in an editorial ca
pacity with two other scientific
publ ications.
He has served on the Board
of Scientific Counselors at the
National Eye Institute, chaired
the Scientific Advisory Com
mittee of the Neurosciences
Research Institute, served on
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the Advisory Council of the
National Institute for Neurological and Communicative
Diseases and Stroke and on
the Medical Advi sory Board
of the Howard Hughes Medical
Institute.
His honors include fellowship in the Royal Society, and
he is foreign associate of the
U.S. National Academy of Sciences (1981) and member of
the American Academy of Arts
and Sciences, Alpha Omega
Alpha, and Institute of Medicine. In 1984, he was awarded
the Karl Spencer Lashley Prize
for Neurobiology by the American Philosophical Society.
He is an associate of the
Neurosciences Research Program and a member of the
International Brain Research
Organization , the Society for
Neuroscience (president 197778), the American Association
for the Advancement of Science, Sigma Xi, the Anatomical Society of Great Britain
and Ireland, the Royal Microscopical Society, the American
Association of Anatomists, and
past president of the St. Louis
Society of Neurological
Sciences.
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wo faculty members
will conduct research
for the next seven years
with almost $1.5 million in
funding from 1avits Neuroscience Investigator Awards.

,

Recipients of the most recent 1avits Award s include
Harold Burton, Ph.D., professor of neurobiology and associate professor of physiology
and biophysics; and David I.
Gottlieb, Ph.D., associate professor of neurobiology and
biochemi stry.
Washington University raculty members have received
eight of the 125 1avits Neuroscience Investigator Awards
presented since October 1983,
when the highly competitive
awards program began. Award
recipients are selected three
times a year.
The U.S. Congress gives the
awards in honor of Sen. 1acob
K . Javits of New York , on recommendation of the National
Advisory Neurological and
Communicative Disorders and
Stroke Council of the National
Institutes of Health. 1avits suffers from amyotrophic lateral
sclerosis (ALS) more commonly known as Lou Gehrig's
disease. ALS is a degenerative
neuromuscular disorder, affecting the nerve cells that control
muscles.
The awards, given to investigators who have submitted
regular research grant applications for competitive review,
encourage research and training in communicative and
neurological pisorders. The
prestigious grants provide a
seven-year commitment of
support to the researchers who
receive them.
Burton'S research is designed to learn more about
neural codes associated with
the sense of touch. His studies
should illuminate the role that
speci fic areas of the cerebral
cortex play in texture perception and the way in which
neuronal activity relates to sen-

sory discrimination behavior.
These experiments may facilitate understanding of how the
cerebral cortex operates in
learning to recognize touched
objects, such as braille symbols
and tactile gra ph ics for the
visually impaired .
Gottlieb's resea rch goal is
to understand the mechanisms
that control the expression of
important neuronal properties
during the development of the
mammalian central nervous
system. He plans to use monoclonal antibodies that recognize
subsets of neurons to determine
when cell-specific antigenssubstances that cause antibodies to form - are first developed. He also hopes to find
out if the formation of appropriate neural connections is
necessary to the development
':I
of cell-specific antigens.

and thus at a higher risk of
cardiovascular disease.
This is the first study of its
kind to examine the effect of
diet on cholesterol levels in persons with that trai t. Researchers will screen volunteers aged
21-60 to select those who have
the trait, as well as a group of
controls who do not have the
defective protein.
Two other studies will test
new cholesterol-lowering
drugs, one in liquid form and
the other in capsule form.
Researchers will use volun
teers aged 21-70 to test for
optimum dosage and long-term
clearance.
More information about any
of the cholesterol studies is
available rrom 1-4 p. m. weekdays at the Lipid Research
Center, 314-362-3500.

'tJl 1I1lf(.(~ I'S

conduct long-term research on
intellectual function in persons
aged 65 and older, seeks volun
teers to participate in studies
comparing healthy aging with
Alzheimer's disease.
The project needs volunteers
aged 65-85 who are experienc
ing some form of memory loss
anciJor dementia without obvi
ous cause. They should not
have other serious di sease, including stroke, heart failure,
lung failure or cancer. For rur
ther information, contact MAP
at 314-362-2683.
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everal resea rch projects
... at the School of Medicine
need volunteers to make
them a success.

The Lipid Research
Center is conducting several
studies on the effect of diet and
medication on blood cholesterol. Among the projects is
a diet study funded under a
three-year, $110,000 grant
from the NIH. According to
the center's director, Gustav
Schonfeld, M.D., an inherited
protein defect that affects 25
percent of Americans is beIieved to make them more
susceptible to cholesterol

The Memory and Aging
Project (MAP), begun at the
School of Medicine in 1979 to

The Diabetes Control and
Complications 1rial (DCCT)
needs persons with insulindependent diabetes to partici
pate in one of the largest and
most important studies of the
disease ever performed. The
DCCT is a seven-year study
that will include 1,100-1,200
participants at 21 medical cen
ters, including Washington

3

University, across the country.
The study, funded by the
National Institute of Arthritis,
Diabetes and Digestive and
Kidney Diseases, seeks to an
swer one of the most important
remaining questions about dia
betes: how effective are some
of the newer forms of diabetes
therapy at preventing, delaying
or reversing the presence of
diabetic complications? These
complications may affect the
eyes, kidney, nerves, heart
and blood vessels.
Participants in the DCCT
must be between the ages of 13
and 39 and have had type 1 dia
betes for 1-15 years. They can
not be taking more than two
insulin injections per day, be
using an insulin pump, or have
any severe complications from
diabetes. Volunteers will re
ceive free medical care for the
next seven years. To volunteer,
contact Julio Santiago, M.D. ,
at 314-454-6051.

or King Fetsch, failing
the vision test for her
driver's license was a
real eye-opener.
Fetsch's low score revea led
something she had not even
suspected - that her eyes were
succumbing to complications
of diabetes. Her poor perfor
mance would lead her to be
come, literally, an eyewitness
to the unfolding legacy of
the laser.
Mrs. Fetsch is one of 92
patients in a landmark study
proving that the laser can re
verse the leading cause of
vision loss in diabetics, a pre
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R. Joseph Olk's recent study proves that the leading cause of
blindness among diabetics, macuJo.r edema, can be reversed
through laser therapy.
viously untreatable condition
known as diffuse diabetic
macular edema. That success
has catapulted the laser, al
ready widely used to repair
retinas and cut away cataracts,
into still another ophthal
mologic spotlight.
The latest focus on laser's
ability to aid lapsing vision
could benefit many people,
says the study 's principal inves
tigator, because the condition
is much more widespread than
its rather obscure reputation
would indicate.
"Macular edema is the
major cause of visual impair
ment in all diabetics," says
R. Joseph Olk , M.D., who con
ducted the research at Wash
ington University. "It doesn't
cause people to go blind, but it
interferes with their ability to
read , drive, maintain a job or
do close work . In other words,
the necessary tasks of Ii fe."
Macular edema, Olk
explains, is a vision-blurring
buildup of fluid inside the eye.
The condition is Jess damaging
to eyesight, but much more

prevalent than the other vision
problem common among dia
betics, proliferative diabetic
retinopathy. Proliferative retin
opathy, a condition in which
the eye's tiny blood vessels
hemorrhage and the retina
sometimes detaches, can cause
legal blindness if untreated.
Of the nearly 6 million diag
nosed diabetics in the United
States (and the American Dia
betes Association estimates
there are 4-5 million undiag
nosed cases), nearly I in 5 re
port some vision impairment.
Retinopathy, which includes
both macular edema and pro
liferative retinopathy, is consid
ered one of the disease's major
complications. It is tied to du
ration of the disease: I in 2
diabetics will develop retin
opathy after ten years with the
disease, and 9 in 10 will after
20 years.
Olk, an assistant professor
of ophthalmology, presented
the first research results prov
ing that laser therapy can al
most always eliminate macular
edema at the annual meeting

of the American Academy of
Ophthalmology in October.
Previous studies have sug
gested some benefits from laser
treatments, but none have
shown such clear results.
A subsequent report from
the Early Treatment of Dia
betic Retinopathy Study, pub
lished in the December 1985
Archives of Ophthalmology,
confirmed the results found in
Olk's study. That study also
demonstrated a positive treat
ment benefit from argon laser
in people who have "clinically
significant" macular edema,
though it used a different treat
ment technique than Olk's.
His new technique, called
"modified grid," reduces fluid
in the macula, a tiny part of
the retina that is most responsi
ble for sharpness of vision
(acuity). Further, Olk reported
that laser therapy preserves 
and in many cases improves
- vision already impaired by
the condition.
Research results published
in 1976 proved that another
laser technique, panretinal
photocoagulation, can reduce
by more than 50 percent the
vision loss caused by prolifera
tive retinopathy. Since then,
laser has become routine treat
ment for those patients.
As Olk points out, though,
those findings did not even ad
dress macular edema, leaving
a much larger group of patients
in an ocular lurch.
"Most ophthalmologists
have told their diabetic patients
that nothing can be done about
macular edema," Olk says.
"They have not considered any
form of laser therapy because
research results have not been
very promising. Until now,
there was no statistical evidence
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that treatment is better than no
treatment. So the majority has
not been treated. Their vision
either has stayed the same, or
slowly deteriorated.
"Now, ophthalmologists can
use our results to recommend,
without question, that their patients with diabetic macular
edema should undergo this
treatment to reduce severe
vision loss."
OLk's findings are based on
a three-year clinical trial of
modified grid photocoagulation. The study was conducted
at the School of Medicine and
Barnes Hospital.
For King Fetsch, the modified grid laser has meant a liberation of sorts. The 56-yearold widow, who received three
treatments in her left eye as
part of OLk 's study, has seen
such an improvement in vision
that her glasses need less
correction for that eye.
"When I first saw Dr. Olk,
he told me that there was no
chance of improving my vision
and only a 40 percent chance
of saving my existing vision,"
she recalls. "He not only saved
it, but he improved it, too. "
She has not experienced the
side effects reported by most
other patients.
The eye that was treated is
now the one she depends on.
Vision in her right eye, a control during the two-year study,
has deteriorated. She has just
had a third laser treatment in
that eye and wi II learn in the
corning months if she'll need
further therapy.
While Mrs. Fetsch waits,
she's optimistic and does what
any good eyewitness would do:
she gives enthusiastic testimony to the effectiveness
of modified grid laser.

"I recommend it ," she says.

"r know a diabetic with the
same condition r have. His
doctor said nothing could be
done. I referred him to Dr.
Olk, and he's had two laser
treatments since July. Your
vision is definitely worth a
second opinion. "
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he C.v Mosby Company and the Times
Mirror Foundation have
announced a $100,000 gift to
endow a pathology laboratory
at the School of Medicine. The
gift is presented as part of the
ALLIANCE FOR WASHTNGTON UNIVERSITY, a $300
million program to provide
support for the institution.
The funding will endow a
pathology laboratory in the
Clinical Sciences Research
Building and will support the
research of department head
Emil R. Unanue, M.D. Unanue
is Edward Mallinckrodt Professor of Pathology at the School
of Medicine and pathologist-inchief at Barnes, Children's and
Jewish hospitals.
An immunopathologist,
Unanue has investigated interactions among immune system
cells. He has been instrumental
in showing the critical role
played by macrophages, cells
which activate the body's
immune response to foreign
invaders. Macrophage interac tions with other immune system cells are important in

organ transplants and in the
body 's response to many disease states, especially infection
and cancer.
The Times Mirror Foundation is the corporate foundation
of Los Angeles-based Times
Mirror, parent company of
C.v Mosby as well as television
station KTVI, Channel 2, and
The Sporting News Publishing
Company, all in the St. Louis
area. Times Mirror publishes
the Los Angeles Times and
seven additional newspapers,
and has other extensive media
holdings.
The C.v Mosby Company
publishes medical and health
care books for students and
professionals, and produces
such electronic publications as
educational software and test!
II
review materials.
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The 1986 Medical Center
Alumni Reunion will be held
May 1-3. Classes specially honored at the reunion this year
include those who graduated
in 1931 and every five years
thereafter, including 1976. For
more information, contact the
Alumni Office at 314-362-8278.
Timothy L. Ratliff, Ph.D.,
research associate professor
and director of urologic research, division of urologic
surgery, has been awarded a
World Health Organization
Travel-Study Fellowship and a
Burroughs-Wellcome Travel
Research Grant to conduct research at the Middlesex Hospital in London, May-June 1986.
Ratliff is currently funded
by the National Cancer Institute and the American Cancer

Society for his research on
BCG therapy for superficial
bladder cancer. The fellowship
and grant permit him to inves
tigate the immune response in
duced by mycobacterial antigens (the active components of
BCG vaccine) in the laboratory
of Graham Rook, a noted re
searcher in the field.
George E. Murphy, M.D.,
professor of psychiatry and
director of the psychiatry
outpatient clinic, has been
awarded a $316,000 grant
by the NIMH. The grant will
support an investigation of cognitive therapy as a specific
treatment for depression. In a
previous study, Murphy dem
onstrated that cognitive therapy
is at least as effective as medi
cation in the treatment of
depressed outpatients. The
present study seeks to find any
specific aspect of cognitive
therapy that would explain its
usefulness in treating this
disorder.
Thomas E Deuel, M.D.,
professor of biological chern istry and medicine and director
of the Fixman Cancer Center
at Jewish Hospital, has been
awarded the 1985 Dameshek
Prize at the annual meeting
of the American Society
of Hematology.
The 1985 Awards Lun
cheon, presided over by Dean
Herweg, was held December
II. At this annual event, firstthrough third-year students are
honored for their academic
prowess during 1984-85. The
prizes, and recipients, are: The

George F Gill Prize in Anatomy,
and The Kehar S. Chouke
Prize in Anotom)\ awarded to
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Kenneth M. Carnes, Robert G.
Kaniecki , and Robinna G.
Lorenz.
The Edmund V Cowdrv Prize
in Hislology. awarded to Robert
J Optican.
The Dr James L. O'Leary
Neuroscience Prize, awarded to
RusselJ E. Hillsley.
The Carl F (Ind Gerry T Cori
Prizes in Biochemistry. awarded
to Richard C. Bell and
Paula J Chor.
The Antoinelle Frances
Dames Prize ill Physiology and
Biophysics, awarded to
Robert 1. Optican and
Kenneth M. Zabel.
The Howard A. McCardock
Book Prize in Palholof?,)\
awarded to Jesse S. Little, Jr.
The DI: Margaret C Smith
Award, given to Laura A.
Rokusek.
The Mediccrl Cenler Alumni
Scholarship Fund Prize,
awarded to James A. Schiro.
The Accrdemic Achievement
Award, given to Albert B.
Ross.
Olil'er H. Lown' Prize ill
Pharrnacology, awarded to
Peter L Smith.
The McGraw-HilI Book
Prizes, awarded to Kenneth M.
Zabel and Russell E. Hillsley.
The Richard S. Brookings
Medical School Prizes, awarded
to Brian A. Armstrong, Jesse
S. Little, Jr., and Eric E.
Stevens.
The Dr Robert Carter Medical School Prizes, awarded to
Jeffrey L Elliott, Robert M.
Forstot. and HalTi ~ S.
Chrysikopoulos.
Morris J. Ka rnovsky,
M,n., Ch.B., D.Sc., deliv-

ered the 32nd annual Robert 1.
Terry Lecture. Karnovsky is a
cell biologist and experimental
pathologist who developed a
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widely used technique to visualize microscopic images. He
is Shattuck Professor of
Pathological Anatomy and
chairman of the Program in
Cell and Developmental Biology at the Harvard School
of Medicine.
The Department of Anatomy
and Neurobiology sponsors the
Terry Lectureship, which was
established by alumni and
friends to honor Terry, who
was department head from
1900-41.
Yasutomi Nishizuka was
the featured speaker at the 28th
Shaffer Lecture, part of a minisymposium sponsored by the
Department of Biological
Chemistry and The Howard
Hughes Medical Institute.
Nishizuka, of Kobe University
in Japan, is an expert on phospholipids (fats), some of which
are involved in the activation of
protein kinase C. The latter
transforms normal cells into
tumorous ones and may be an
important regulatory aspect
of the process.
Philip W Majerus, M.D. '61.
professor of biological chemistry and medicine , was another
of the symposium speakers. He
described his work on specific
phospholipids that encode information in their structure.
These compounds are "second
messengers" and are part of a
system analogous to adenylate
cyclase / cyclic AMP The
Iipids Majerus investigates
show a particular structural
shape in cells stimulated to
form tumors.
H. Gobind Khorana presented the first Carl and Gerty
Cori Lecture. Khorana, now in
the departments of biology and
chemistry at Massachusetts
Institute of Technology, worked

at Washington University when
Arthur Kornberg was here.
Khorana was awarded the
Nobel Prize in 1968 for his
work on the genetic code. His
presentation for the Cori Lecture described bacteriorhodopsin, a bacterial protein that is
a light-driven proton pump.

J. Michael Bishop, M.D.,
was the thirteenth Carl Vernon
Moore lecturer. Bishop, professor of microbiology and immunology, is director of The
Hooper Research Foundation
at the University of Cali fomi a,
San Francisco. His topic was
"Oncogenes: Trouble in our
DNA." Oncogenes are activated when cells form tumors
U.S. Sen. Thomas F.
Eagleton, D-Mo., delivered
the third annual Edward Massie Lecture in Cardiovascular
Disease. His talk, titled
"Health Care's Third Revolution - Sowing Seeds for the
Fourth?", honored Edward
Massie, M.D. '35, professor
emeritus of clinical medicine.
Eagleton, a U.S. senator
since 1969, has been very involved in funding health care
research, particularly through
the National Institutes of
Health. He was instrumental
in establishing the National
Institute on Aging, and in the
mid-1970s played a key role in
passage of the Health Manpower Act.
Frederick Sweet, Ph.D.,
professor of reproductive biology, has received more than
$900,000 to continue studying
the role of enzymes in producing steroid hormones. The
four-year grant renews a previous award to Sweet from the
National Institute of Child
Health and Human Develop-

ment. Sweet hopes his research
eventually will lead to improved management of fetal
development during pregnancy
and to a better understanding
of how hormones are produced
in the body.
In previous animal studies,
Sweet and another investigator
isolated and described an enzyme that they believe forms
part of a unique hormonal
communication system between the fetus and mother.
They think similar communication systems function
throughout human pregnancies.
Sweet's research is in con
junction with three separately
funded laboratories, including
one headed by James C. Warren, M.D. , Ph.D. , professor and
head of obstetrics and gynecology. The other laboratories are
in Australia and Massachusetts. The investigators are collaborating on two other projects that examine the role of
enzyme systems important in
the production and regulation
of hormones.
The WU School of Medicine chapter of the Alpha
Omega Alpha medical fraternity initiated fourteen newly
elected senior medical students
at its annual banquet.
The new members are
Trevor C. Axford, Nancy L.
Bartlett, Charalabos Harris
Chrysikopoulos, Bradley A.
Evanoff, Fredric 1. Gross,
Rachel F Haft, Daniel H.
Hechtman, 8avid A. Johnson,
Jean P MoJJeston, Michael E.
Presti , James A. Schiro, Eric
E. Stevens, 0. Clark West , and
Judith L Zier.
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he Diagnostic Interview Schedule
(DIS), a tool for diagnosing specific
mental disorders, was born at Wash
ington University. Now fully matured , it's
traveling the world. From Iceland to main
land China, from Portugal to Puerto Rico,
researchers are using the DIS and its 22
translations in clinical and epidemiologica l
studies.
Only a few years have elapsed between
the DIS's conception and this spate of
globe-trotting. The need for such a tool be
came evident in 1978 when the President's
Comrni ssion on Mental Health , asking how
the mentally ill are served, concluded that
information about the prevalence of mental
di sorders ought to be linked to data on the
use of mental health facilities. But at that
time, there was no comprehensive infonna
tion on either topic.
Epidemiologic studies of mental illness
in the US. began in 1855, when physician
Edward Jarvis tried to determine the fre
quency of the two major diagnoses of that
era, insanity and idiocy. Later, other disor
ders - such as depression and anxiety
were defined and surveyed. But after World
War II , most American epidemiologi sts
either rejected the tenet of multiple di sor
ders or decided that psychi atri sts were unre
liable diagnos tici ans. So subsequent studies
measured blanket mental iJlness instead of
different di sorders. Result: Some question
able conclu sions about the mental hea lth
of America ns. For example, the Midtown
Manhattan Study, publi shed in 1962, co n
cluded that 82 percent of its sample had
psychiatric problems.
During the 1960s and 70s, opi nion swung
once aga in to favor specific diagnoses such
as sch izophreni a, mani a and depression .
And during that time, psychi atrists devel
oped tools to define the different di sorders,
eliminating the greatest source of error in
diagnosis: variation in diagnostic criteria
from one psychiatrist to another.

T

A psychiatric diaglwstic illterview written by Lee N Robins, lejf, al/racted sponsorship
from NIMH because it ejfectively ullmasked low-prevalmlce disorders ill )'ery large pOpll
liJlioll studies. Elizabeth M. Smith is examining the melltal health ofpersollS v.posed to
jloods, dioxill alld radioactive well wata

One such tool , the Research Di agnostic
Criteria (RDC), grew out of ten yca rs' re
search on di agnosis, much of it under the
directi on of Eli Robins, M.D. , then head of
psychiatry at Washi ngto n University and
now Renard Professor of Psychiatry Today,
th e Diagnostic and Statistical Manual of
Mental Disorders (DSM-III), which evo lved
from the RDC, is the official diagnostic
system in the U.S. and is widely used
elsewhere.
The DSM-IJI was in preparation when
the President's Commission announced its
findings in 1978. So when NIMH took up
the Commission's cha llenge and decided to
conduct a nationwide survey of mental
health , it wanted to use DSM-I/J criteria.
It also had to fi nd a survey method.
Early surveys assessed mental disorder
by inspecting officia l records and ask ing
leaders about severely disturbed people in
their communities. So they missed all but
the obvious cases. Later, psychiatrists began
to do personal interviews but refrained
from asking "e mbarrassing" questi ons
about sexual behavior, violence and drink

ing. More recenrly, they discovered that
people are willing to admit to "deviant" be
havior, and their interviews have become
more comprehensive.
Assessing the written interviews ava il
able in 1978, NIMH concluded that one de
veloped by Lee N. Robins, Ph.D , professor
of soc iology In psychiatry, and her col
leagues at Washington University, was
closest to it s requirement. "Jt formed the
best base from which to begin :' says Darrel
A. Regier, M.D, M.PH .. then head of the
Division of I3iometry and Epidemiology al
NIM H, now director of NIMH's Clinical
Research Division . "We needed an inter
view that cou ld be administered to a very
large population in order to assess di sorders
that are found at very low prevalence. In
order to conduct such a large-scale survey,
we knew that we would have to use Illy in
terviewers, which meant that the interview
had to be highly structured. It had to repli
cale as much as possible the clini cal diag
nostic proce~s."
IMH sc ienti sts sponsored and coordi
nated the development of a new diagnostic
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interview. Working with John E. Helzer,
M.D., professor of psychiatry, and Jack L.
Croughan, M.D., clinical associate profes
sor of psychiatry, and scientists Robert
Spitzer and Janet Williams from the New
York Psychiatry Institute, Lee Robins con
verted the interview into the DIS by incor
porating DSM-III criteria, adding questions
about the recency of symptoms and making
it scorable by computer. Then in 1981, the
DIS took to the field in the five areas of
NIMH's survey, which was caJled the
Epidemiological Catchment Area (ECA)
study.

DIS JN THE FJELD
The study assessed the prevalence (life
time occurrence) of specific mental disor
ders in and around five American cities.
Between the two study phases, a telephone
survey asked about the use of mental health
facilities. The same people were inter
viewed on all three occasions.
The ECA study is the largest psychiatric
epidemiologic study to date, each site being
nearly as big as the combined total of all
previous North American studies. With
3,000 household residents and 500 institu
tionalized residents at each site, the study
surveyed nearly 20,000 people age 18 and
older. Regions of inner cities were also in
cluded because of their known high rates
of psychopathology.
The interviewers - mostly market re
searchers and census data collectors 
trained for eight days, where they learned
how to ask the DIS questions and code the
answers. They needed no prior knowledge
of psychiatry because the questions are read
exactly as written and because the computer
makes the final diagnoses. The only tricky
part was learning to use the probe flow
chart, the interview's "road map." The
chart directs the interviewer to a subsequent
question on the basis of the previous ques
tion's answer.
After training, the interviewers took their
expertise into homes and institutions, where
they conducted the interviews. The results
were then collected, cleaned and analyzed,
giving the first assessment of the prevalence
of 15 mental disorders. Incidence figures
are not yet available.
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Felton J Earls is using the DiagIWstic Interview Schedule, DIS, devewped at Washington
University in his assessments oj mental illness among adolescent populations. He says the
DIS overshadows all the other existing interviews.

MENTAL HEALTH IN AMERICA
The study found that about one-third
of the sample had experienced at least one
psychiatric disorder sometime during their
lives. The most prevalent diagnoses were
alcohol abuse, phobias, major depression,
antisocial personality (chronic amoral and
impulsive behavior), and drug abuse.
There was no difference at any site
between the total prevalence of disorders
in men and women. This contrasts with
earlier surveys, which consistently found
that women have more psychiatric illness.
" It appears that the reason for this repeated
earlier finding," conclude the research
ers, "was that symptoms of the male
predominant diagnoses such as alcoholism,
drug dependence and antisocial personality
were little inquired about."
Researchers also uncovered a surprising
relationship between age and incidence of
mental disorders. They expected to find
higher rates in older persons, who have been
at risk for longer periods. But alcohol abuse,
major depress ion , mania and panic disorder
were least prevalent among those over age
65. Drug abuse was highest among 18- to
24-year-olds. The drug abuse results are
understandable, the researchers say, because
the drug epidemic began in the late 1960s.

But the other findings have no ready
explanation.
Unlike the age-related findings, the effect
of urbanization on mental health was pre
dictable. Inner cities had higher rates of
drug abuse, antisocial behavior, schizo
phrenia and cognitive impairment. Only
panic di sorder was higher in the rural and
small-town areas.
The study also showed that fewer than
one-fifth of persons with recent symptoms
had visited either a general physician or
mental health specialist to discuss psychiat
ric problems in the previous six months.
And though about one in two schizophren
ics and one in three people with affective
disorders (mania, depression) had sought
help, the ratio was only one in ten for
persons with alcohol-related problems.
"It was su spected before our study that
there was a lack of treatment for substance
abuse, but no one could put a number on
it," says Lee Robins. "And what was most
interesting to me was not the numbers so
much as the barriers to treatment. Things
that are easy to remedy - such as cost,
opening hours of clinics, or not knowing
where to get help - are not very frequent.
People with alcohol problems think that
they should be able to stop drinking on their
own, that it's not a proper thing to talk to a
doctor about, or that it's a bad habit that

,

How to Write Leading Questions
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they will overcome. So they don't think it's
a reason to seek care. I think that's a very
important finding . It means that the prob
lem is not just to improve facilities but also
to educate the publ ic. "

NEW STUDIES SPAWNED
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Since the completion of the ECA study,
Washington University has continued to
work with the DIS. Helzer and Robins are
among collaborators developing a computer
based DIS that can be either self
administered or given by an interviewer.
And a computer-based screening interview
will help general physicians distinguish pa
tients with psychiatric disorders from those
with physical illness. Next year, the re
searchers hope to computerize an interview
called CIDI (Composite International Diag
nostic Instrument), a combination of a
British interview and the DIS.
Other studies using the DIS as a diagnos
tic tool include the Health Effects of Envi
ronmental Hazards, in which Lee Robins
and Elizabeth M. Smith , Ph. D., research
assistant professor of social work in psy
chiatry, are looking at the mental health of
persons exposed to flood s, radioactive well
water and dioxin , and the Health in Teens
Study headed by Felton 1. Earls, M.D ,
Blanche E IttIeson Professor of Child
Psychiatry.
The Health in Teens Study (HITS) com
pares adolescents (ages 10-13) treated in tra
ditional public health clinics with those
cared for by consolidated clinics that pro
vide a network of comprehensive services.
An adolescent with multiple problem s could
visit a clinic for, say, pregnancy but not re
ceive treatment for her depression or drug
abuse. In 1980, the Robert Wood Johnson
Foundation supported establishment of 20
consolidated clinics, each a network of ser
vices providing comprehensive treatment.
HITS evaluates the performances of seven
of these compared with three traditional
clinics in ten different cities.
Fieldwork began in 1984, when HITS
interviewed 3,000 adolescents who visited
one of the clinics for any medical purpose.
Using parts of the DIS plus the related
Diagnostic Interview for Children and Ado
lescents, it diagnosed the disorders that
were present in the sample. Then in No-

"Writing an interview is really more
an art than a science," says Lee Robins.
"There's little in the literature about
it except for rules about not leading
the respondent with biased questions
and not combining two ideas in a single
question ."
Compiling the 259 sets of a main
question plus subquestions in the DIS
began with a list of psychiatric symp
toms compiled from DSM-I1I. For
example, psychiatric researchers need to
know about a client's possible heavy al
cohol intake, recklessness, violence and
job loss - symptoms of alcohol abuse.
So they had to write understandable
questions that would uncover any of
these symptoms. "That's the hard part,"
says Robins. "A question has to be per
fectly clear, short and mean exactly what
you think it means."
The questions also had to be non
judgmental and inoffensive. "Do you
have trouble getting along with people?"
would probably provoke most persons to
respond, "No." So a series of more tact
ful questions was needed: "How many
times have you been divorced? Other
than when you separated just before a
divorce, have you and your husband ever
separated for a few days or longer be
cause of not getting along? Did you
separate more than once?"
The Interview was tested on small
groups of people, and any ambiguous or
offensive questions were rewritten and
tried out again . After about 50 such pre

vember 1985, HITS re-interviewed the same
adolescents and also reviewed medical re
cords. After this wave is completed in May
1986, it should reveal any differences in the
effects of the two types of health care on the
lives of adolescents.
Earls says this study would be impossible
without the DIS because of the tremendous
cost of using psychiatrists for diagnosis.
"Other questionnaires for lay interviewers
do exist," he says, "but whereas they may
have been partially tested for reliability, the
DIS has been exhaustively tested for preci
sion and accuracy. So the DIS overshadows
all the other existing interviews."
In May 1986, data from DIS-based
studies in Asia , Europe and North America
will be compared at a meeting of the Amer

tests, the DIS was ready for the field .
The probe-flow chart grew out of the
psychiatry department's conventional
way of asking questions. Like other
physicians, psychiatrists probe patients
to assess the significance and physical
basis of symptoms, but they don't usually
work from a script. The chart provides
lay interviewers with written instructions
for routine and efficient questioning.
Following these, an interviewer asks
a patient who admits to frequent head
aches, "Did you tell a doctor about your
headaches?" A " Yes" elicits, "When you
told your doctor, what was the diag
nosis?," whereas a "No" prompts, "Did
you tell any other professional about
your headaches?" Each subsequent
answer likewise leads to one of two or
more questions or tells the interviewer
to enter a code for later diagnosis.
The Interview was evaluated during
the largest national survey of mental
illness ever made in the U.S. - the
Epidemiological Catchment Area study.
During the ECA, lay interviewers' re
sults were compared with diagnoses
made by psychiatrists using several
diagnostic methods including the DIS.
Since there was good agreement on
many items between the different meth
ods, researchers feel optimistic about the
DIS's validity for clinical and epidemi
ologic studies. However, the real test will
come in learning how well it predicts the
respondent's future problems and his or
her success in seeking care.


ican Psychiatric Association in Washington,
DC. Moreover, the World Health Organiza
tion is presently testing the CIDI prior
to a large epidemiological study in nine
countries.
Thus, CIDI - an outgrowth of DIS 
and the DIS itself must surely make states
men envious. These psychiatric tools enable
cross-cultural differences to be neutralized
and diagnostic disputes settled , paving the
way for progress in psychiatric diagnosis.
Perhaps leaders in the arena of world poli
tics would do well to emulate the vision and
creativity of researchers at Washington
University.
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NESIN
ANEW CELLULAR MOTOR
BY SUZANNE HAGAN

Zipping along microtubule "tracks, " organelles create a
flurry oftraffic in cells. Kinesin, a unique cellular protein,
piggybacks the organelles across the cell's vast inner
spaces. But how to view this hidden world in
the laboratory? Washington University researcher
Michael Sheetz has coated tiny glass beads with kinesin.
Using videotape and a microscope, Sheetz monitors the
movement ofthese kinesin-coated beads, enabling
him to analyze the properties ofthis newest member of
the family ofmotile proteins.

I'
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iniature railroad enthusiasts know
- but probably couldn't explain
the fascination that this hobby
holds. Even a casual observer can't help but
be mesmerized by the sight of a locomotive,
with a shri II whistle and puffs of smoke,
chugging ceaselessly around the railroad
track. Through tunnels and train stations,
over hills and trestles, the locomotive
continues its journey.
There is a risk of being mesmerized by a
different sort of transport system when you
visit the laboratory of Michael P Sheetz,
Ph.D., professor of cell biology and physi
ology. A video screen in Sheetz's lab bears
an enhanced microscopic view of certain
cellular contents, hair-like fibers called
microtubules. While the viewer watches,
these microtubules seem to take on a life
of their own. They become mini-railroad
tracks, with barely visible " locomotives"
zipping along on their surfaces - some
times in only one direction, other times
in the opposite direction. And some loco
motives careen toward each other as if bent
on a head-on collision: They don't stop
or slow down, yet they don't col Iide. As
if directed by some unseen engineer, the
mini-locomotives streak past each other,
continuing unimpeded .
"On video tape," says Sheetz, "we see
dramatic examples of multiple tracks on
single microtubules, with organelles passing
each other going opposite directions." View
ing microtubules with an electron micro
scope provides the explanation . These hair
like fibers are each made up of 13 or 14
tinier fibers called protofilaments. Each pro
to filament is a separate track, enabling or
ganelles - the tiny "locomotives" that zip
along the microtubules' surface in cells 
to avoid collision. Sheetz and co-workers
have discovered that this movement along
microtubules is powered by a unique cellu
lar protein, kinesin.
Kinesin is the most recently discovered
protein that powers movement. Kinesin,
along with another motile protein called
cytoplasmic dynein, propels the smallest
of organelles from one part of the cell
to another.
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The most well-known of the cell's motile
proteins is myosin. Its sliding action along
actin filaments, worked out by Hugh and
Andrew Huxley in 1954, is the basis for
muscle movement. For many years after
the Huxleys' classic studies, researchers
searched for the proteins that power the
movement of substances inside cells. Dynein
was the next motile protein to be uncovered.
It propels cilia and flagella of some single
celled organisms through a fluid medium .
All cells need to move the smaller
organelles within their cytoplasm , like the
membrane-encased droplets that form at
the cell's surface when it takes in sub
stances. And a nerve cell needs to quickly
move organelles and substances from the
cell body - the neuron's "headquarters"
-to the tip of its axon, a distance of up to
a meter or more. But no one knew how this
was accomplished. Many scientists thought
that dynein, or a dynein-like protein, was
responsible.
In August 1985, Sheetz and his collabo
rators at Woods Hole and Stanford pub
lished the news of their discovery of kinesin.
"In essence," muses Sheetz , "kinesin and
dynein provide a pair of motors that move
objects in two directions along micro
tubules. A microtubule - which is larger
than a single actin filament, with a lot more
structural stability - can support two di
rections of movement. " And because of the
proto filaments on each microtubule, bi
directional movement can be accomplished
without collision.

\\ ( HIIH ('1111 '"
Microtubules form a fine mesh, a micro
skeleton within cells. "There is one major
microtubule-organizing center in the cell,"
explains Sheetz, "and that's the centriole or
centrosome. From that emanates all the
cell's microtubules. Recent studies suggest
that this organizational structure gives the
cell a directional polarity. It's very easy with
a motor like kinesin, which moves sub
stances from the centriole to the periphery,
to set up a traffic pattern going from the
centrosome to the cell membrane."
Sheetz and co-workers think that a
cytoplasmic dynein, or a protein similar to

dynein, moves substances in the opposite
direction - from the cell membrane
toward the cell's center. ATP provides the
energy that drives both of these motor
proteins.
The assay system Sheetz uses is simple.
It consists of microtubules stabilized by at
tachmentto glass. To that is added the
motor (kinesin), a source of energy (ATP),
and something to move. A good substitute
for fragile organelles are small latex beads,
and these are the barely visible locomotives
that can be observed zipping along the mi
crotubules. Kinesin has an affinity for both
the beads and the microtubules, "walking"
along the laller in a movement that Sheetz
descri bes as " ... hand over hand. Perhaps
the best analogy for all motile proteins is
that they move somewhat like a centipede.
There are probably at least ten 'heads' or
'arms' reaching out from the protein and
interacting with the appropriate filament.
In the case of kinesin or dynein, that's a mi
crotubule; in the case of myosin, it's actin."
As these motile proteins " walk" along their
filament, they don't let go; one arm is
always attached.
Sheetz has performed similar experi
ments with myosin-coated beads: "I always
joke when I go to seminars that I've thought
about forming a company that would make
myosin-coated shoes," he says with a laugh.
"But not many people would want shoes
that would require an actin 'roadway' and
only let them move at five micrometers per
second."
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Sheetz is buoyed by the fact that kinesin
seems to be ubiquitous among species:
"We've found kinesin everywhere we've
looked." Recently, his group has developed
an antibody to kinesin, enabling them
to spot the protein no matter where its
biological home.
In collaboration with Ursula Good
enough, Ph.D., professor of biology, kine
sin's possible role in the movement of a
single-celled organism will be explored .
"Everywhere we've looked," says Sheetz,
"from vertebrates to invertebrates, from
cows' cells to sea urchins, we've found
kinesin . And in all those systems, we've
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gotten movement to occur and found that
the polarity of kinesin movement along
microtubules is the same."
And in all these systems, kinesin powers
the movement of organelles at approxi
mately the same rate, but that's no surprise
to Sheetz: "All our experiments are in the
test tube, outside of the cell, so there's no
inhibition of movement by surrounding
cytoplasm. When you go into cytoplasm,
however, there's a dramatic three
dimensional network - a latticework or
cytoskeleton - in which there are pores of
varying sizes. The organelles that are mov
ing along microtubules are roughly the
same size as these pores or gaps in the
cytoskeleton. Consequently, they're con
stantly bumping into it. To the extent they
adhere, they slow down. So it's thought that
the cytoskeleton acts as a molecuJar sieve,
and that it's inhibiting the movement of the
large organelles more than it's inhibiting
the movement of smaller ones."
For unusually shaped cells like neurons,
in which a long projection - the axon 
extends away from the cell body, " we be

Michael Sheetz slwws his video system thal demonstrates kilU!sin-powered movement to
second-year student Emily Dohe.
lieve that kinesin is the motor which drives
objects from the cell body to the synapse,"
says Sheetz. "We believe that the motor
driving things from the synapse back to the
cell body is the dynein-like protein we're
trying to isolate."
This work will continue at Washington
University in collaboration with Mark B.
Wi liard, Ph. D., professor of neurobiology
and biological chemistry. Sheetz is also
working with Robert H. Waterston, M.D.,
Ph.D., associate professor of genetics and
anatomy and neurobiology, on different
types of myosin from mutant worms. They
want to know how in vitro movements of
myosin-coated beads correlate with the un
usual movements that can be seen in worms
that have these mutations in muscle myosin.
Together with Elliott L. Elson, Ph.D., pro
fessor of biological chemistry, Sheetz will
study movement of intact cells on cover-

slips, to see what relative roles kinesin and
myosin play in this type of cell movement.
Sheetz continues collaboration with his
long-time Woods Hole colleague. They are
cloning the gene for kinesin to investigate
the "nuts and bolts" of which amino acids
are linked together to form the protein.
"With the tools we have now," says
Sheetz, "the video systems, the gene clon
ing, the antibody production techniques 
it's possible to take a phenomenon, such as
axonal transport, and go quickly from the
phenomenon to a protein - cloning the
gene - in two years.
"We know what kinesin is, but there are
many unresolved questions," he continues.
"How is kinesin controlled? What tells an
organelle to move? There are some ques
tions that are harder to crack than others.
But now the technology is in hand to ad
dress a number of problems that were out
of reach before."
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TRANSPLANTING

BY KAREN BURNS

he immune system is both ally and
adversary to the human body. lts
warriors, so adept at fending off
ominous foreign microorganisms, have also
stubbornly resisted entry of the good guys
- hea.lthy organs needed to replace those
that are diseased and dying.
This battle is truly one of life or death.
But thanks to the persistence of the medical
community, organ transplantation is enjoy
ing its greatest success ever. Immunosup
pressive therapy, surgical acumen and other
advances such as monoclonal antibodies
and cryogenics are improving the odds fa
voring organ transplantation; now it is pos
sible for seriously il I patients to be restored
to near-normal. Although the cost of a
transplant remains high, many insurance
companies that once viewed the operations
as experimental (and therefore refused
coverage) are beginning to pick up the tab.
At Washington University School of
Medicine, success is most evident in the
ever-growing list of organs transplanted:
Liver, heart, cornea, pancreatic cell, and
long-bone transplants - called allografts,
or homografts, because they are from one
patient to another - are joining the well
established kidney transplant program (600
done to date). Revival ofan old idea is
underway in the transplantation of aortic
and pulmonary homograft heart valves, and
the tiny incus and stapes of the middle ear
have joined the list, too. Preparations are
also being made for clinical heart-lung
transplantation, and small bowel transplants
are being studied in the lab.

T
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Autotransplantation - the process of
transplanting an organ in the same body 
continues to be viable therapy in plastic sur
gery, where distant components of the body
are used to reconstruct faulty areas; skin is
being transplanted in burn patients; and
bone marrow autografts are helping people
survive the treatment for certain types
of cancer.
But even with these advances in organ
transplantation, we've won only half the
battle. According to the Journal oftile Amer
ican Medical Association (.lAMA), almost
20,000 people will suffer brain death from
trauma this year, yet only 15 percent will
become organ donors. And there are at least
100,000 potential recipients nationwide,
more than 100 in St. Louis alone . .lAMA
says the organ shortage is exacerbated by
several factors: people fail to will their
organs before they die; family members re
fuse to donate the organs of the dead; hospi
tal personnel neglect to ask for organ dona
tions; available organs cannot be matched
with recipients; and organs are allocated
improperly. A bright spot is that multiple
organ donors are increasing, sometimes al
lowing as many as ten recipients to benefit
from the organs from one donor.
Some states are considering - and oth
ers have passed - required request laws.
.lAMA states that as a result of those laws,

M. Wayne Flye is director ofthe organ
transplantation program at Washington
University.

physicians will be required to notify the
nearest organ procurement agency when
brain death occurs in patients who have
willed their organs. Upon brain death in
a person whose wishes regarding the fate of
their organs are unknown, physicians will
be required to request that the family
consider organ donation.
According to M. Wayne Flye, M.D.,
Ph.D., professor of general surgery and di
rector of the organ transplantation program
at Washington University, the best way to
donate an organ is to make the decision
"out of the stress" of the catastrophic event.
"[t is really up to each individual," says
Flye, "to make a decision to donate organs
before death, and to make this wish known
to family members so they can carry it out."
Flye says that physicians should also
examine their feelings about organ trans
plantation so they are prepared when a
donor is available. Because of increased
public awareness of organ donation , more
and more families initiate donation when
death of a loved one is near. (A January
1983 Gallup Poll showed that 93 percent of
those polled were aware of organ transplan
tation and of those, 72 percent said they
would give permission to donate kidneys or
other vital organs; 80 percent said they were
aware of organ donor cards.) Flye adds that
physicians themselves often donate the or
gans of their deceased fami Iy members:
"We're seeing more and more of that," he
says. "And it's just as difficult a decision
for them."

TRANSPLANTSUCCESSSHAREO
Flye came to Washington University last
year to perform the center's first liver trans
plants at Barnes Hospital, and he is pleased
with the results. Overall, Washington Uni
versity's transplant success rates are com
parable to those at other major transplant
centers: kidney transplants here have an
80-85 percent success rate; livers, a 65-75
percent success rate; hearts, 80-85 percent;
and corneas and long bones, almost
100 percent.
As quickly as he quotes success rates and
extols the merits of transplants for the recip
ients, Flye just as quickly - almost in the
same breath - remembers the donors with
deep gratitude. "Transplantation of these
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living ti ssues is only possible because of the
generosity of anonymous donors and their
families," stresses Flye, attending surgeon
at Barnes, Children's and Jewish hospitals.
Heart transplant surgeon R. Morton
Bolman Ill, M. D., assistant professor of
cardiothoracic surgery who came to Wash
ington University last year, agrees and adds:
"It is incumbent upon us as physicians and
healthcare personnel to be aware of the
need for donated organs so others can be
given a chance to live."
Washington University is among the
growing number of select medical centers
that have a mUlti-organ transplant program.
The university's transplant team, which in
cludes six nurse coordinators, is on call 24
hours a day. In addition, the university is
affiliated with the Mid-America Transplant
Association and is plugged into the national
computer lines that record available organs.
The transplant team also has a jet on 24
hour standby that flies them on " lifeguard"
status. The status gives them top-priority
air space for optimum travel time. The jet
and other up-to-date procurement tech
niques make it possible for them to retrieve
and use any organ from almost any dis
tance. 'The transplant surgeons here have a
personal commitment to making thi s a fine,
active transplant program," says coor
dinator Judy Dickens, R.N. "They spend a
good part of their time and effort not only
directing it, but also going out and imple
menting it." (Heart transplants have been
performed at both Barnes and Children's
hospitals.)
Much of the success of organ transplanta
tion, here and elsewhere, has been due to
immunosuppression by cyclosporine, either
alone or in combination with other drugs.
Washington University was one of the first
to use a regimen of cyclosporine combined
with Imuran and prednisone; heart trans
plant surgeon Bolman says the combination
relieves blood pressure and kidney com
plications created when cyc\osporine is
given alone.
Another reason for the success is that
doctors are more selective of their recip
ients, who should be free of other disease
and have good overall function of other
organs.
The oldest and best-established compo

nent of the university program involves kid
ney transplants, which are the only trans
plants other than bone marrow that involve
a living donor. The program began in 1963
and has been actively promoted and directed
by Charles B. Anderson, M.D., since 1973.
"Kidney transplantation is now the pre
ferred method of treating most patients with
end-stage renal disease, especially those
younger than 55," says Anderson, head of
general surgery. "But even though it's a rou
tine operation, it's still an evolving field .
We have a lot to learn. "
Anderson and his colleagues want to
learn why some kidney transplants work
and others don't.
Kidney transplants have long been a via
ble alternative to dialysis, partly because of
Medicare's early decision to be responsible
for providing treatment for permanent end
stage renal failure. At Washington Univer
sity, the living/re/ated transplant's success
is primarily due to donor-specific blood
transfusions, a method that was developed
here in 1971. The protocol involves trans
fusing the kidney donor's blood to the recip
ient three times over the six weeks before
the transplant is performed. At the same
time, the recipient is given immunosuppres
sive drug therapy. The process "tricks" the
body into accepting foreign tissue and has
resulted in an 85-90 percent success rate,
says Anderson, general surgeon-in-chief
at Barnes Hospital.
Anderson's transplant group is also
studying immunosuppression with azathio
prine, as well as trying to identify methods
of decreasing rejection by altering prosta
glandin production. Another area of re
search is the donor-recipient relationship
between husbands and wives; those trans
plants so far have been successful.
A major advance in fighting renal allo
graft rejection is in the area of monoclonal
antibodies. Flye and hi s colleagues recently
published the result s of a study of OKT3 
a murine monoclonal antibody that reacts
with , and blocks the function of, the T3 an
tigen on human T cells. In a study of 129
patients, rejection was reversed in 71 per
cent, with 61 percent of the grafts function
ing after 12 months. The study showed that
OKT3 is an effective treatment for acute
renal allograft rejection that is uncontrol
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Charles B. Anderson has directed the kidney transplnnt program since 1973.
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lable by present conventional treatments.
"With the addition of heart and liver
transplants, this has become one of the pre
miere centers in the world for transplanta
tion - both clinically and experimentally,"
says Anderson, attending surgeon at Chil
dren's and Jewish hospitals.

OLD IDEA HEBOB.N
One of the newest areas of organ trans
pl antation at Washington University in
volves aortic and pulmonary valve allo
grafts. The operation was first done in 1962
in England and New Zealand but didn't be
come popular in the U.S.: Techniques for

sterilizing, storing and preserving the valves
resulted in shortened graft function. Xeno
grafts and mechanical valves were the main
stays, despite side effects like thrombo
emboli sm and infection, and difficulties
with anticoagulation and hydraulic func
tion. All these problems cause significant
morbidity and mortality and are especially
troublesome in younger adults and children.
This group has had a five-year complication
free survival rate as low as SO percent.
New preservation methods have changed
all that, according to Richard A. Hopkins,
M.D. , assistant professor of cardiothoracic
surgery, who performs valve transpl ant op

erations. The technique - using antibiotic
ste rilization and DMSO-liquid nitrogen
freezing (a technique similar to that used
for preserving sperm) - has made human
valves a viable alternative. Some of the ad
vantages include nature's better engineering
design, resulting in optimal function, and
freedom from thromboembolism and he
molysis. Also, larger valves can be fitted
into smaller patients (for better perfor
mance) and the patient doesn't need to be
anticoagulated , as is needed with mechani
cal valves. Since the procedure is often
done in small, active children, not needing
to give anticoagulant s is significant, says
Hopkins.
Another significant difference between
heart valves and other transplanted organs
is that the patient doesn't need immunosup
pressant therapy, though the reasons aren't
yet clear why valve leaflets resist rejection,
says Hopkins, attending surgeon at Barnes
Hospital. Excellent valve function has per
sisted in some patients for up to IS years.
"This [valve transplants] will eventually
take place in all medical centers doing state
of-the-art surgery because the performance
of these valves is so much better," says
Hopkins, who trained in London at The
Great Ormond Street Hospital for Sick
Children, where SO such operations are per
formed a year. "I tell my patients that the
engineer on this valve is a lot better than
any of our engineers - the valves are really
better than anything we could make. "
Donated valves come from hearts that
are not transplantable. The procedure to do
nate the valves is the same as any organ
if a donor is available, a transplant center or
agency should be called. And, like sk in,
corneas and long bones, the valves can be
removed for up to 12 hours after the donor
has died, and can be stored almost indefi
nitely. This differs from the vital organs
kidney, liver, heart and heart-lung - that
must be removed from the brain-dead
patient before the heart stops.
Heart valves, like all transplantable
organs, are life-saving. Unfortunately,
physicians can't save every patient from
death. However, through transplantation,
they can grasp back from death something

that is good: life.

17

lIiiiiiiiii

TlIE

ETHER SCREEN
BY SUZANNE HAGAN

ewsweek calls them the "doctors you

N

can't see." They're the anesthesiolo
gists and anesthetists - physicians
and nurses - hidden behind the ether
screen . They staff the intensive care units,
snatch the dying from death 's grasp, and
give the gift of relief to patients suffering
chronic pain. They're the untouted "intern
ists of the operating room ," who help in
the surgical miracles that happen every day.
Giving anesthesia to any patient, says
William D. Owens, M.D., Mallinckrodt
Professor and head of anesthesiology, is
very much like conducting an orchestra: "In
anesthesiology, many potent drugs that allay
consciousness and pain must be titrated 
carefully administered in measured doses
- for an individual patient. A poor titration
is much like what you hear as a symphony
orchestra is warming up; sounds come from
every which way and none of it is harmo
nious. When anesthesia is titrated properly,
though, it 's like an orchestra playing beauti
ful music.
"In one sense, anesthesia's safety hasn't
really changed much in the last 35 years,"
reflects Owens. "The mortality related to
anesthesia in healthy young people is about
one in 10,000. That's about the same as it
was in the late 1940s. But on the other
hand, we're taking sicker and sicker people
to the operating room and doing more ex
tensive, prolonged surgery on them. So
even though the numbers are about the
same, we must be improving on safety or
those other patients would have rai sed the
mortality and morbidity."
Anesthesia has progressed remarkably
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since the days of ether, which posed a con
siderable explosive hazard and made pa
tients extremely nauseous. " We can sedate
people without totally removing them from
their conscious state, " says Owens. "It's not
the same as the ' twilight state,' which for
merly was used during labor and delivery
and took advantage of anesthetics we don't
use today. But the end result is much
the same."

GOING UNDER
The anesthesiologist must make alJow
ances for the weakened physiological state
of the patient about to undergo surgery.
Another important consideration is the type
of medication the patient may be taking.
"Someone with rheumatoid arthritis may
take a great deal of aspirin, which increases
bleeding time - such patients' blood
doesn't clot as well ," points out Owens.
"Consequently, blood loss is higher, and
there's a greater chance of needing a trans
fusion in these patients. There are inter
actions between many of the heart medica
tions and anesthetics, and between many of
the tranquilizers and sedatives - the sleep
ing piJJs people take at home, even the over
the-counter medications. It's very important
that the anesthesiologist know what medica
tions a patient is taking. We can work
around them in most cases; there are only
a few that we need to have them taken off."
Carey I. Weiss, M.D. , instructor of anes
thesiology and director of anesthesiology
for organ transplants at Barnes Hospital, has
been involved in every liver transplant that's
been done at the medical center. Weiss, also

acting director of cardiac anesthesiology, is
pleased with the progress of the organ trans
plant program. But he points out that popu
lar perceptions of anesthesiologists' duties
are rife with misconceptions: "As anesthe
siologists, we need to provide the patient a
comfortable and anxiety-free perioperative
period and provide for the goals of anes
thesia - amnesia and analgesia. But a lot
of times, that's not the hardest part of
our job.
"We must achieve analgesia and amnesia
in a way that causes no harm to come to the
patient and in many cases, enhances the pa
tient's condition, and that's very difficult,"
he continues. 'The other part of our goal,
in addition to patient comfort, stability and
preservation of homeostasis, is to provide
an adequate - if not ideal - work ing envi
ronment for the surgeon.
"If only pentothal was as perfect as peo
ple think it is," muses Wei ss. "We simply
don't have in our armamentarium the

Carey I. Weiss directs anesthesiology for
organ transplants at Barnes Hospital.
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anesthetic drug that will accomplish all
these goals. What we need to do, for most
patients, is pick out a balance of imperfect
drugs. In cardiac anesthesia, many drugs
can provide anesthesia, but they all have
different liabilities for the heart or lungs.
Our job is to know the patient's patho
physiology well enough, and our phar
macology well. enough, so we can pick the
right drug combination without pushing
things to the toxic level."
Anesthesiology is really a meld of phar
macology and physiology, says Weiss;
neither is more important than the other.
Cardiac anesthesia may be made up of
perhaps a dozen drugs. "Benzodiazepines
will be used to produce part of the anmesic
state, as well as scopolamine," Weiss says.
"For profound analgesia, high doses of po
tent opioids are commonly used. That still
doesn't help us provide the immobile field
- muscle relaxation - required by the sur
geon, so we'll use a muscle relaxant. All of

those we'll try to blend because they also
interact with the cardiovascular and pulmo
nary systems in ways other than producing
anesthesia. Some will raise heart rate, some
will lower heart rate, some will depress the
heart's ability to work, some will increase
the heart's ability to work. All of them we
try to blend to provide a smooth and stable
course for the patient."
Liver and heart transplants involve fun
damentally different considerations, says
Weiss. Although in both, the overwhelming
problem is the major defective organ, pa
tients who need a liver transplant have
healthy hearts, with good cardiac reserve.
Their problems are determined by the
specific type of liver pathology affect
ing them.
"If the pathology is an impedence of por
tal blood flow," says Weiss, "then we'll get
into all the problems of portal hypertension
and enlarged collateral venous tracts, and
all the bleeding that will create, together

with the possibilities of gastrointestinal
hemorrhages and varices - just a legion
of problems from one perturbation. Most
transplant patients with liver problems have
low blood albumin and poor nutritional
status. That changes the way you need to
induce anesthesia.
"An impaired liver can't produce proteins
that clot the blood. There will be a cascade
of interrelated problems that need to be
handled. If we're doing a good job for the
surgeon and the patient, all the surgeon has
to worry about is the procedure. Our job is
to take care of the patient in such a way that
homeostasis is preserved. That means that
as blood or fluid is lost, we replace it, or as
any other changes occur, we work to keep
the patient on an even keel."
Several liver transplants have been per
formed on children, the youngest only six
months old, entailing special considerations
for this group of patients. 'They're not just
small adults," points out Weiss. "Their
physiology is different."
Weiss collaborates with pediatric anes
thesiologists to select just the right drug,
or assortment of drugs, to enable the surgery
to proceed smoothly. But medical problems
are only one facet of the problems faced by
anesthesiologists. Patients about to undergo
surgery may be overwhelmed by anxiety.
"If their health dictates that they need to
have some operation," says Owens, "we can
tailor some kind of anesthetic for almost
anyone, and do a good job of helping them
pull through the operation and take care
of them post-operatively.
'The fear of the unknown is by far the
biggest fear," he concludes. "Patients would
do themselves a big favor if they would just
open up with their anesthesiologist before
surgery and let the questions come out, be
cause we can answer them. No one should
put off having anesthesia and surgery today
because they think it's too risky."
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orne people take the direct route
to get where they're going in life;
others meander around a bit Scott
Selleck, a fifth-year student in the Medical
Scientist Training Program (MSTP), is a
meanderer. "[ moved around a lot when [
was growing up," reports Selleck, a native
of Saskatoon, Canada. "[ lived in Brussels
from when 1 was six years old until 1 was
about II." Another move to Ithaca, NY,
allowed Selleck to finish high school and
enroll in a marine biology program, spend
ing 1976-77 at a field station in Grenada.
After transferring to McGill University for
a year, he moved to the U. of Washington
in Seattle, where he finished his studies
in marine biology.
After graduating with a RA. in zoology,
he couldn't find a job in marine biology,
partly because as a Canadian, he couldn't
work for any U.S. national oceanographic
concerns. To make ends meet, he hired on
as a cashier in a bus depot for eight weeks.
Finally, he got a job as a hospital technician
in Seattle, spending two years researching
drugs that produce defects in embryos, to
see what role maternal metabolism exerted
in either causing the defect or protecting the
embryo. It was this job that kindled his in
terest in returning to school and the M.ST?
(medical scientist training program, whose
graduates earn an M. D. and Ph. D.) at
Washington University.
'Td actually not thought about going
into medicine but was interested only in
research at that point," remembers Selleck.
But he elected to work for a while as a vol
unteer at the hospital, to get an idea of what
clinical medicine was like. And that was
another turning point in his life. He met
many patients who were in desperate emo
tional straits. Some had no families ; others
were dying or suffering from chronic ill
nesses: " You get a perspective on what
you're doing in the lab by working with
patients," he reftects. "It emphasizes how
research is much more than simply an
intellectual game."
Today, as a student who's completed one
year towards his M.D. and is enmeshed in
research towards his Ph.D., Selleck doesn't
stray much outside the environs of the labo
ratory of John E. Majors, Ph.D., assistant
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Scott Selleck is "Big Brother" to Sean Sedach. Selleck was honored in September for his
longterm participation in the Big Brother/Big Sister Program sponsored by the Jewish
Community Centers Associntion. (plwto by David Henschel)
professor of biological chemistry. There,
using yeast DNA, he looks for "footprints"
that demarcate the chromosomal points
where the production of m-RNA - the
" messenger" that directs protein synthesis
- first begins.
Yet his busy research career doesn't
eat up all his time. He participates in the
JCCA's Big Brother program. His two years
as a Big Brother have been as rewarding for
him as for his Little Brother, Sean Sedach.

"I like the questions that Sean asks me,
things that maybe he wouldn't ask his
mother. And it gets me out, doing the things
1 like to do but wouldn't have made time for."
As far as Sean is concerned , having a Big
Brother is the perfect complement for the
"grueling" life of an II-year-old fifth
grader: "We do lots of things together," says
Sean, "like go to [St Louis Soccer] Steam
ers games, or to the museum, or bowling or
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golfing. We' ll usually go out to eat, too."
They see each other once a week or every
other week , says Sean , and between milk
shakes and movies, there's plenty of time
for talking: "We talk about lots of things,"
says Sean, "like my problems, or anything
going on with me."
In appreciation for Selleck's participa
tion, the JCCA honored him last September
as "Big Brother of the Month ." Taking ad
vantage of opportunities like the Big
Brother program isn't unusual for someone
like Selleck, whose future isn't confined
to a university research setting.
One of the appealing things about the
MSTP is that it increases his options for the
future, says Selleck: "Graduates can go into
pure science, or clinical work, or even a
government job setting health policy. The
education we receive trains us for an amaz
ingly wide variety of positions in research
and health care."
Currently, Selleck is one of 92 students
enrolled in MSTp, a program begun 16
years ago thanks to a then-new National
Institutes of Health program channeled
through the National Institute of General
Medical Science. In 1969-70, ten students
enrolled in the Washington University pro
gram initiated by Roy Vageles, M.D.,
Ph.D. , then chairman of the Department of
Biological Chemistry and now president
of Merck and Company, Inc. The program
concept was vigorously supported by Luis
Glaser, Ph.D., Carl Frieden, Ph.D., and
Barbara Fox. Today, these same three per
sons (Glaser and Frieden are co-directors,
and Fox is assistant director) still steward
a training program that is, according to Lee
Van Lenten, M.D., the national program
administrator at NIH, "one of the top pro
grams in the country. It's very successful
- our peer review group just returned from
a site visit there, and they were very favor
ably impressed."
In 1964, when the NIH first provided
funding for medical scientist training pro
grams, only three schools participated.
Today, reports Van Lenten, 25 schools
across the nation - with 683 students 
receive funding from the NIH for their pro

gram, supported by grants totalling $12.6
million.
The NIH's MSTP grant provides about
half the support needed for the WU pro
gram, says Fox, with the university provid
ing the remainder. "Without the university's
support, we couldn't enroll the number of
students we do," reports Frieden. Several
schools, he says, have only NIH support and
can accept only a small number of students.
"Thus far," says Frieden, "we've gradu
ated about 90 students. About half have
completed their residencies, and almost all
are in research settings today. Our success
rate in training academic scientists, skilled
in clinical and basic research , is even better
than the NIH envisioned."
Frieden heads the MSTP admissions
committee, which has representatives from
all the preclinical departments at the School
of Medicine as well as the Department of
Medicine. "The faculty is very committed
to, and enthusiastic about, the MSTp," says
Frieden. "These students represent a really
top-notch groufl, and they're fun to have
around . At any given time, they represent
about a fourth of our graduate students, and
they contribute enormously to that group.
They enhance both graduate and medical
education. "
"The MSTP was the first inter
departmental educational program we ever
had," says Glaser. "It set the stage for the
formation of the Division of Biomedical
Science. The MSTP and our graduate pro
gram benefit from each other since they
each attract a unique flavor of student."
The NIH is keenly aware of this advan
tage and has boosted support for this pro
gram through the years, says Van Lenten.
"In 1979, the NIH spent about $7.7 million
to support 666 students," he reports.
"Today, we fund about the same number of
students - 683 - but it costs much more,
$12.6 million. The monetary increase has
been primarily in tuition increases, although
we have increased the amount of the
stipend." Currently, Washington University
provides each MSTP student with a stipend
of $7,250.
One of the program's strengths, says
Frieden, is the fact that it only accepts
students who have done some research .

Another, pointed out by Van Lenten, is the
strong recruiting program: "They have gone
out even to the smaller schools and made
themselves known," he points out. "Not
every university does this."
So what kinds of students does the pro
gram attract? Very good ones, like Scott
Selleck, with strong academic records and
proven ability as researchers. "In many
ways, Scott is typical of the student who
comes through the program ," muses
Frieden, "but he's perhaps had a more di
verse range of experiences. Overall , this is
a group of students who can simultaneously
do a number of things well."
"Our students are perhaps our greatest
challenge," says Fox with a laugh. "Carl
Frieden and Luis Glaser are really open to
student input when it comes to program
policy and procedure. Student suggestions
are implemented whenever feasible, and
they have greatly influenced the direction
this program has taken. Scott is one of our
most active students, and he really keeps us
on our toes."

EDITOR'S NOTE
The hard-working and enlhusiaslic admis
sions committee for the MSTP currently con
sists ofthe following members in addition to
Glaser and Frieden: Irving Boime, Ph.D.,
professor ofpharmacology and obstetrics/
gynecology; Thomas J Braciale, M.D.,
Ph.D., associate professor ofpathology;
Jonathan B. Cohen, Ph.D., professor of
neurobiology and biological chemistry; Paul
J DeWeer, MD., Ph.D., professor ofcell biol
ogyandphysiology; Elliot L. Elson, Ph.D.,
professor ofbiological chemistry; Ted H.
Hansen, Ph.D. , associate professor ofgenet
ics; David!. Gottlieb, Ph.D., associate pro
fessor ofalUltomy and neurobiology and bio
logical chemistry; David Schlessinger, PhD. ,
professor ofmicrobiology and immwwlogy
and medicine; John L. Schultz (ex officio),
assistanl dean and registrar, School ofMedi
cine; Douglas Tollefsen , M.D. , Ph.D. '77,
assistant professor ofbiological chemisuy
and associate professor ofmedicine.
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The
We're
BY DON CLAYTON

fter several years "back at the
drawing board," researchers at
Washington University and else
where are now ready to begin major clinical
trials of a drug thought capable of increas
ing up to two-fold the effectiveness of anti
cancer radiation thcrapy.
The drug SR-2S08, when present in
a tumor, helps ensure that the damage
caused by radiation treatments will be
irreparable and lethal to cancer cells, says
Todd Wasserman, M.D., radiation therapist
at Washington University and chairman of
the group that will test the drug on cancer
patients.
Hopes are high for SR-2508 because lab
tests and an initial clinical trial indicate the
drug enhances radiation and penetrates
tumors more uniformly than previously
tested drugs. In addition, SR-2508 does not
exhibit the major side effects that have
forced physicians to hold the dose of other
"radiosensitizers" to less-than-effective
levels.
Results of the Phase I clinical trial
and plans for wide-scale Phase III test
ing at 15 to 20 U.S. and Canadian medical

A

Cross section through two lobes ofa solid
tumor. Researchers are using "sensitizing"
agents to make cells between the tumor's
core and periphery more sllsceptible to
radiation therapy.

centers were announced during the Confer
ence on Chemical Modifiers of Cancer
Treatments, held recently in Clearwater, FL.
Wasserman. involved in radiosensitizer
research tor eight years, chaired the session
in which the SR-2508 report was presented.
The report reflects data from trials at Wash
ington University, Stanford. University of
Calit()rnia-San Francisco, and University
of Alberta in Canada.
"The safety of SR -2508," says
Wasserman , "enables us to give doses
three times higher than we could with other
radiosens.itizers. Because of the way SR
2508 is administered and the way the body
handles the drug, it can be given to patients
on a schedule compatible with the five
times-a-week schedule preferred lor radia
tion treatments."
Phase III clinical trials of SR-2508
will be conducted by the Radiation Therapy
Oncology Group (RTOG), funded by the
National Cancer Institute. Twenty-one med
ical institutions arc currently full members
of the RTOG, although each does not neces
sarily participate in every study.
The SR-2508 trials, scheduled to be
underway by mid-1986, will involve a vari
ety of tumors including advanced bladder,
prostate, and head and neck cancers.
Wasserman, chairman of the RTOG com
mittee coordinating the trials. says that
Washington University researchers will use
the drug on selected patients with each of
these types of cancer.
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"These trials will include hundreds of
patients, and should take from three to five
years," Wasserman says. SR-2508 will be
given intravenously three times weekly
throughout a standard course of radiation
therapy, five to six weeks. Patients who
receive the drug and radiation will be com
pared to similar patients who receive
radiation but no SR-2508. As in the past,
Washington University patients will be ad
mitted to the General Clinical Research
Center during the administration of their
therapy.

EARLY FAILURES
The sensitizer that oncologists have the
most experience with is mi sonidazole, or
"miso," a precursor to SR-2508. By the late
1970s, several institutions had begun clini
cal trials with miso. While some of miso's
properties made it appealillg, others soon
led to problems. Administered in pill form,
miso caused nausea and vomiting. It could
cross the blood-brain bar rier and cause
nervous system side effects.
"In the time that I was involved in miso
therapy here at Washington University, I
can't remember encountering any patients
who remained on the medication long

enough to develop central nervous system
toxicities," recalls Faye Jennings, a super
visory nurse in radiation oncology. "How
ever, other centers did report such effects."
Wasserman, with James S. Nelson, M.D.,
a Washington U. pathologist, confirmed that
miso could cause observable physical dam
age to the myelin sheath around peripheral
nerves.
"The neuropathy reported was always
temporary, but sometimes severe," says
Wasserman. "There were reports of the
same type of peripheral neuropathy we still
have with SR-2508, but there were also re
ports of patients who had exhibited a state
of confusion during their course of therapy.
On top of that, even when we thought that
ample doses of miso penetrated the tumor,
the cancers didn't respond as well as pre
dicted. The severity of the side effects dis
couraged researchers from further increas
ing the dose of miso administered.
"Considering all the factors pointing
toward success, miso's failure made it in
cumbent on us to find out what the problem
was," recalls Wasserman. "The whole area
of research fell into a slump while we
retrenched. "
The National Cancer Institute asked

several teams of chemists and biologists to
develop rni sonidazole analogs, hoping that
some might be even more potent radiosen
sitizers but lack miso's side effects. Stanford
Research Institute developed SR-2508.
"Our initial clinical trial was crucial be
cause it would have indicated whether
SR-2508's toxicities were similar to miso's.
Administered intravenously and at dose
levels three to four times greater than miso,
we saw some side effects. But none was se
vere enough to abandon SR-2508 as the best
alternative to miso," says Wasserman. "No
toxicities from such a drug would be best,
but at least SR-2508 's side effects are pre
dictable, reversible and don't overlap with
any of the side effects from radiation ther
apy or the cancer itsel f."
According to reports at the Florida meet
ing, only 25 percent of the 103 patients
tested to date have complained of nervous
system side effects related to SR-2508 ther
apy. 'Those complaints," adds Jennings,
"have been peripheral neuropathy, ex
pressed as a numbness or tingling sensation
in the extremities. Most patients describe
the sensation as a feeling of 'pins and nee
dles' or of having the limb' fall asleep. '
To ensure the earliest detection of these side

't'
f
Todd Wasserman chnirs the group tho.i will
test the radioJion-enhancing drug SR-2S08
on cancer patients.
effects, the nurses and physicians regularly
ask patients if they are experiencing such
feelings. The neuropathy always disappears
when the treatments are halted. The tin
gling sensations subside gradually. Within a
two-month period, most patients can report
some improvement."
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The radiation-enhancing, or radiosen
sitizing, properties of drugs like miso and
SR-2508 are based on the cellular charac
teristics of solid tumors. On cross section,
most tumors larger than a walnut reveal
three regions that are distinguishable by
their proximity to blood supply and, there
fore, by the amount of oxygen they receive.
The tumor's core, most removed from the
capillaries, is so oxygen poor that the tissue
is essentially dead and poses minimal
threats to the patient. The outer ring of the
tumor is closest to the blood supply. These
peripheral cells siphon enough nutrients and
oxygen from the blood to fuel the tumor's
rapid, invasive expansion. The mid-region
of the tumor, between the core and the outer
ring, contains cells that are dormant , a state
some liken to a "metabolic suspended ani
mation. " They lack sufficient oxygen for
rapid growth but can revitalize if the sur
face of the tumor is stripped away, provid
ing better contact with the blood supply.
The oxygen-rich cells on the tumor's sur
face respond to chemotherapy and standard
radiation therapy because these interven
tions kill cells that are metabolically active
and dividing. The oxygen-poor cells in the
mid-region are protected from current
therapies by their suspended animation.
During a tolerable course of therapy, the
treatments wipe out the peripheral cells.
But after therapy is suspended, blood-borne
oxygen revitalizes the remaining cells, and
a relapse can occur as the tumor begins
again to increase in size.
The oxygen-poor, or hypoxic, region
of tumors was documented 30 years ago:
William Powers, M.D., and Leonard
Tolmach, Ph.D., both of Washington u.,
were among the first to confirm the pres

ence of the hypoxic region. When scientists
realized that the hypoxic cells had a natural
defense against radiation and chemotherapy,
they set out to find ways of increasing the
oxygen content of a tumor's hypoxic area.
One of the earl iest methods for raising
the oxygen content of these cells was what
Wasserman calls the "sledgehammer ap
proach." Patients were placed in a high
pressure oxygen chamber in the hope that
the high pressure would drive so much oxy
gen into the blood that some of it would
diffuse to the tumor's central regions.
Hyperbaric oxygen therapy was abandoned
in the late 1960s for several reasons. The
treatment was expensive, uncomfortable
and difficult to administer safely.
]n the mid-1970s, misonidazole came
along. Laboratory tests with tumor cells,
and later animal trials indicated that miso
nidazole could, like oxygen, help increase
the cancer cells' DNA damage caused by
radiation therapy.
"The intriguing thing about miso is that
it offered us the opportunity to have a sim
ple, orally administered sensitizer that could
be given right before radiation treatments,"
says Wasserman .
Miso and its safer derivative, SR-2508,
mimic the biochemical properties of oxy
gen. "Radiation damages DNA in the cells
it enters," explains Michael Welch, Ph.D.,
a Washington U. radiation chemist who has
conducted considerable research on miso
and miso derivatives and has collaborated
with Wasserman. "]f an oxygen molecule
or any other molecules with certain proper
ties of oxygen are present in the tumor cell,
that cell's DNA is more likely to sustain a
double-strand rather than a single-strand
break. The cell has mechanisms for repair
ing single-strand damage, but a double
break is usually lethal."

FOOI1S GOLD
"The body's cells treat SR-2508 like
fool's gold," explains Wasserman. "Each
cell passes the drug along. Eventually, SR
2508 accumulates selectively in hypoxic
cells, making it an ideal radiosensitizing
agent. It has a specificity for just the group
of cancer cells we are after."
'This selective accumulation of miso and
SR-2508 was something that was observed

before it was predicted," adds Welch.
"While we still don't understand why miso
and its derivatives are deposited preferen
tially in hypoxic tissue, we can nonetheless
imagine many ways that such drugs could
be used. They have great potential . Hypoxic
tissue is either the cause or the result of a
wide variety of diseases, including stroke
and myocardial infarction as well as cancer.
Because of this great potential, we have
been working to prepare and manipulate
miso analogs as radioactive drugs."
Welch, along with a former Washington
University researcher now working at the
University of Washington, Kenneth A.
Krohn, Ph.D., has demonstrated that a miso
analog tagged with radioactive fluorine can
be used as a positron tomography scanning
agent. "In our animal studies, we've con
firmed drug accumulation in tumors, and
mapped damaged brain tissue," continues
Welch . "Our guess is that it will be equally
effective at outlining heart damage caused
by myocardial infarct, and that it will be
able to penetrate almost any other tissue
we're interested in examining."
In the immediate future, labeled SR-2508
could well be used to help study how the
radiosensitizer penetrates a tumor, resulting
in information that could help optimize dose
schedules and dose levels. Labeled SR-2508
or other miso derivatives might also become
useful diagnostic tools for the oncologist,
revealing the presence and growth stages of
secondary tumors, and perhaps even help
screen high-risk patients for cancer.
Clinicians will investigate several addi
tional possibilities as clinical trials proceed,
Wasserman predicts. While intravenous
injection seems a reasonable way to ad
minister SR-2508, several researchers
wonder if the drug could be injected
directly into the tumor.
Although SR-2508 looks promising,
several other sensitizing agents are on the
horizon. Each of these will be tested on its
own. "Also," says Wasserman, "we'l] ex
amine whether these different agents can
be combined to increase their therapeutic
effects. "

25

r;7~~La.R

/()l'

;~, J f) ()

Death in Peace or in Pieces
oltaire had reached the ripe old age
of 81 when he wrote this, a remark
able age for his generation. He could
not have written it two centuries later, in
\986, because the otolaryngologist would
have restored his hearing, the ophthalmol
ogist would have removed hi s cataracts, and
the orthopedist would have give n him two
total hip replacements. Furthermore, his
heart disease would have been alleviated
with a coronary artery bypass, and he
would have received a kidney transplant
to restore his renal function. Howeve r, it is
obvious that Voltaire's cerebral functions
were active, and that was hi s good fortune,
because even with our technological
achievements today, we could not have
restored the "fail ing soul. "
Today, the medical profession , the legal
profession , sociologists and ethicists are in
a qu anda ry Technological advances in med
icine and biomedical innovations can main
tain respiration , circulation, metabolism
and excretion into old age. But sooner or
later, the brain deteriorates; what do we do
then ? Let us consider the following patient:
An 87-year-old woman , mentally incom
petent, fell as she was trying to get out of
bed in the nursing home where she had
been for four years. She was brought to hos
pital, where it was found she had several
fractures of the left thigh. She had a history
of cardiac failure. She was not oriented to
time, place or person, was obviously dehy
drated and anemic, weighing 85 pound s,
with two bedsores. She was not in severe
pain. Because of a total hip replacement
that had been performed ten years pre
viously, and the nature of the present frac
tures, the surgical opinion was that the only
feasible operation was a total amputation
of the left leg, a so-called hindquarter
amputation.
Should this patient with chronic brain
syndrome have her leg amputated? If she
survives, she will return - still with cogni
tive brain function lost - to permanent
disability in the nursing home. Or should
she be made as comfortable as possible in
her present condition? Obviously, the pa
tient has a right to govern any intrusion of
her body, but this patient's chronic brain
syndrome made such decisions impossible.
Failing that, her relatives should be con-
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It is true that I am rather
deaf, rather hi ind and
rather crippled and that
all this is capped by
three or more atrocious
inl'irmities; but nothing
deprives me of hope.
VoHaire, 177;'5

suIted; but in this instance, there were none.
Therefore, the ultimate decision rested with
the attending physician, who may be uneasy
with the concept that a certain patient may
need less intervention, not more.
Society and physicians face such dilem
mas more frequently as the proportion of
our aged population grows. Now 29 million
or 12 percent of the population , it will dou
ble by the turn of the century There are
currently no official guidelines, and hope
fully there never will be - every situation
involving the terminally ill presents a
unique set of circumstances. Yet the enor
mous and increasing cost of Medicare sets
the federal bureaucracy rumbling with the
dilemma, how to contain costs? Inevitably,
concepts about death will have to adapt to
circumstances. In the last 20 years, medical
technologies have mushroomed. They pre
serve life at all costs - hence the growth
of intensive care units. As Landau and
Gustafson have stated, a "crusading mental
ity" has come into being, and almost any
means are justified to delay the e nemy,
death. But " the real enemies are disease,
discomfort , disability, fear and anxiety"
Individual groups attempt to solve these
dilemmas. In 1984, under the auspices of
the Society for the Right to Die, a group
of physicians published "The Physician's
Responsibility Toward Hopelessly III
Patients." It indicates that any mechanical
or surgical intervention should be discour
aged if it does not make the patient comfort
able. Moreover, they believe that "severely
and irreversibly demented patients need
only care to make them comfortable. Sense

less perpetuation of the status quo is deci
sion by default."
In Canada, a Law and Reform Commis
sion, composed of leading lawyers, has
established a "Protection of Life Project."
After pointing out that committing euthana
sia and aiding suicide are criminal acts, they
discussed factors culminating in the deci
sion to end medical treatment, thus leading
to death. They indicate that the value of life
should be considered, not only from a
"quantitative" perspective but also from
a "qualitative" viewpoint. Incompetent pa
tients should have the right to die in peace
and dignity, assisted by palliative care.
Practically speak ing, what can be offered
to assist the patient who wants to end life
in peace and dignity?
In 16 states today, including Missouri ,
a " living will" law permits a person to pre
pare a written statement of the care pre
ferred in the event of a terminal illness.
Such a statement is useful to the attending
physicians and spares relatives from making
heart-rending decisions.
Recently, an independent state-wide body,
Oregon Health Decision, undertook a proj
ect to address and resolve problems relating
to: I) the rationing of health care, exacer
bated by the push to contain costs; 2) tech
nological advances that outrace the ability
to pay for, or even understand , them; and
3) the protection of the "autonomy and dig
nity of dying patients from the tyranny of
treating for treatment's sake" (lAMA 254:
3213-6, December 1985). Among other
things, this project has heightened the pub
lic 's awareness of the di lemmas and their
solutions.
We all face problems created by care of
the failing older patient. The primary aim
of medical professionals has become preser
vation of life at any cost. Perhaps, death in
a peaceful and humane fashion may provide
more "salvation for the soul. "
C Ron Stephen, MD., CM

Clinical professor ofanesthesiology
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n his spare time, second
year student John Constan
tino is making a baby ...
a MacBaby, to be precise.
MacBaby shows, in step-by
step fashion, the developmental
events that transform the hu
man egg into a fetus. Constan
tino's extracurricular tinkering
with the Macintosh computer
is supported by the Medical
Alumni Association via its
Teacher of the Year award.
Four-time winner Roy R.
Peterson, Ph.D., professor of
anatomy, used the funds from
this award to purchase the
computer and software and to
pay Constantino to develop the
animated drawings.
MacBaby portrays, in three
dimensions, an overview of
human development. The com·
puter "movie" grew out of
Constantino's frustration that
surfaced several times over the
course of his pre-medical
career - his inability to
mentally picture the three
dimensional events that occur
in biological phenomena.
"Embryology always inter
ested me," says Constantino.
"When I started my first-year
studies, I took anatomy, which
included an embryology sec
tion in the course and an elec
tive. In one of those classes,
they flashed up a slide - a pic
ture of a bilamjnar germ disk.
It looked to me like a swim
mjng pool. When I saw it, sud
denly everything I'd been
struggling with just clicked.
"A few months later, I was
studying for a final in histology.
We were studying the placenta ,
but I never had really under
stood the anatomjcal relation
ship between the placenta and
the embryo. I thought, 'There's
got to be a better way to under
stand how they relate.' Then,
I remembered the swimming
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Roy R. Peterson (left) and John Constantino have created a computer "Inovie" that charts the
course ofdevelopment from egg to embryo.
pool picture. And I got so ex
cited thinking about how it all
fit together that I blew off
studying for my histology test,
and jllSt spent the rest of the
night making sketches."
Soon after, Constantino
showed his sketches to Peter
son and Jane PhillipS-Conroy,
Ph.D., his anatomy and em
bryology instructors, respec
tively; he wanted to write a
book: "I was prepared for them
to laugh me right out of their
offices, but they didn't. They
were very encouraging."
It was Peterson, though,
who came up with the idea of
creating a computer movie
rather than a book. Constan
tino, no hacker, wasn't enthusi
astic; he'd had no experience
with computers. But a few
weeks of learning to manipu
late the Macintosh mouse
through MacPaint (an easy
to-use software package), then

mastering VideoWorks (the ani
mation program), won him
over. Since he had already
thoroughly researched the em
bryological events he wanted
to portray, the only time
consuming part was creating
the individual drawings neces
sary for animation .
"The program makes it easy
to move images from place to
place on the screen," explains
Constantino. "But in order to
make the shape of an image
change - which most of em
bryology really is - you have
to draw separate pictures
for each change, just like a
cartoon. In ordinary two
dimensional drawings, it's im
possible to see the twisting and
folding that are the important
embryological events. And
that's the important thing to
understand - how this ball of
cells can twist into layer upon
layer, and invaginate upon it

self. Once you understand that,
the rest you can get out of
a textbook. "
MacBaby portrays the for
mation of the basic body plan,
including the three germ layers
and the "tube within a tube"
design of the body.
"I think the program has
gone about as far as it can be
cause the more complicated,
further developments require
more attention to detail," says
Constantino. "But I would like
to get in two more systems 
the uro-genital system, and the
formation of the circulatory
system - how the heart devel
ops, and the switch from pla
cental to mature circulation."
Peterson's role included
meticulous checking of the sci
entific events Constantino drew
and the narrative text describ
ing these events. "I made lots
of mistakes on the science,"
says Constantino, "but Dr.
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Peterson never made one
change without telling me first
and asking me what I thought.
He tells me, 'This is your story
- you tell it your way, I don't
want to interfere, because I like
the way you say things.' "
Constantino explains that
this is Peterson's natural style,
one that he displays in his role
as anatomy instructor for all
first-year students: "He never
forces his way on anybody 
he wants people to learn on
their own . He knew that be
cause I had just learned all this
myself, I could teach others to
go through the learning pro
cess. He knows that each stu
dent must go through the learn
ing process on his own, in his
own way. Dr. Peterson's just the
ultimate teacher."
Peterson traveled to San
Francisco in January, at the
invitation of Macintosh, to
participate in a three-day dem
onstration of computer applica
tions. His was one of 24 univer
sity exhibits showing either
software or teaching programs
that had been developed for the
Macintosh by academic institu
tions. Repeatedly, says Peter
son, the $15-a-head visitors
expressed admiration for
Constantino's work.
Once back from the confer
ence, Peterson phoned the
software company, who had al
ready heard of Constantino's
work : ''The person who an
swered the phone said, 'Oh,
yes, MacBaby. Your disks
caused us to rewrite our pro
gram,' " remembers Peterson.
He explains that the original
version of VideoWorks called
for text to be entered as a
graphic, which takes more
memory. The revised version
of the software will allow MacBaby to be compressed to one
or one-and-a-half disks from

its present three-disk version .
Eventually, says Peterson,
they may market Mac Baby
after Constantino finishes the
uro-genital and circulatory sys
tems. ''The student evaluations
of John's work have been very
positive," reports Peterson,
who asked first-year students
to give them feedback on the
movie. "We plan to use it as
a supplement to the textbookonly phase of the course. And
people who stopped by our
exhibit at the conferencephysicians, lawyers, and non
scientists - all said the same
thing: ' I wish I'd had that when
I took embryology.' "
''The things I like are
simple," muses Constantino,
whose goal is to go into family
practice or general surgery.
"I want to find a niche where
somebody needs me; I don't
want to compete with anybody,
even though I'm a very com
petitive person, because that
misses the point."
His goal in creating MacBaby, he says, "derived from
my frustration as a student,
sitting in lecture and wonder
ing, 'Where did that come
from?' I thought, if nothing
else, I wanted to leave nothing
out in describing how to get
from an egg to an embryo. Dr.
Peterson knew I felt that way
and that it would take time to
use such an approach. Yet, he
still said, 'Do it one step at
a time - don't compromise
your view because of time,
do it right.' And t11at's what
we did."

Edward W. Cannady,
M.D. '31, and Robert W.
Elliott, M.D. '36, are chairing
the reunions of their respective
classes at the 1986 Medical
Alumni Reunion.
Kenneth A. Koerner,
M.D. '41, is hosting his class
at this year's reunion.
Virgil Loeb, M.D. '44,
clinical professor of medicine
at Washington University
School of Medicine, has been
elected vice-president and
president-elect of the American
Cancer Society. Loeb is a med
ical oncologist at Barnes
Hospital.
Willard B. Walker, M.D.
'46, invites his former c1ass
mates to the festivities at this
year's reunion .
James W. Owen, M.D.
'46, and Everett R. Lerwick,
M.D. '48, are medical director
and owner, respectively, of the
Lerwick Clinic, newly opened
in downtown St. Louis. The $7
million facility will eventually
have 30 full-time physicians
who supervise diagnosis, out
patient surgery, and preventive
medicine.
J. Neal Middelkamp,
M.D. '48, professor of pediat
rics at Washington University
School of Medicine, has been
elected secretary-treasurer of
the American Board of Pediat
rics. He is a member of the
board's residency review
corruni ttee.
Elizabeth Happel, M.D.
'49, has been honored by the
New Milford Hospital board
for her role in the Connecticut

hospital's building campaign
and her 29-year practice there.
Happel, who has delivered
more than 5,500 babies, will
discontinue practicing obstetrics but provide gynecology
services. She plans to train in
microsurgery so that she can
specialize in treating infertility,
which includes performing
reverse sterilizations.
Happel has contributed to
many professional corrunittees,
including the medical educa
tion corrunittee of the Maternal
and Child Care Division ,
which she headed. She also
served as medical staff repre
sentative to the hospital's
board.
Happel completed residen
cies at Bellevue Hospital and
French Hospital in New York.
Before moving to Connecticut,
she taught at several New York
hospitals. Recently recertified
by t11e American Board of
Obstetrics, Happel was recog
nized by the AMA for her con
tinuing medical education.
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Walter A. German, M.D.

'51, contributed an editorial on
tort reform as a legislative
priority to the Missouri State
Medical Society Magazine,
Missouri Medicine. German is
president of that organization.
Marvin E. Levin, M.D.
'51, welcomes his former c1ass
mates to the 1985 Alumni
Reunion. In addition, he has
led the Medical Eliot Society to
a new milestone: In only two
years, he and his corrunittee
have secured the endowment
for the second Alumni En
dowed Professorship by enlist
ing 145 new members. What's
more, the corrunittee has led

."

the medical school halfway
toward the endowment needed
to fund the third AEP "I think
we can do it by July," says
Levin.
The goal is to eventually
endow one AEP in each of the
School of Medicine's 18 clinical
and preclinical departments.
"When you're in a great place
like Washington University
Medical Center," remarks
levin, "it generates good feel
ings; helping the institution is
only a reflex . It stimulates you
to want to do something for
those yet to come, to leave a
heritage - excellent teachers.
lowe this place something."
Robert E. Hermann,
M.D. ' 54, heads the board
of the American College of
Surgeons. Hermann, chairman
of the Department of General
Surgery at Cleveland Clinic
Foundation, was elected last
fall to represent the 220 gover
nors on the association's Board
of Regents. He joined CCF in
1962 after completing intern
ship and residency in surgery
at University Hospitals of
Cleveland.

Robert E. Hernuum

Richard W. Hudgens,
M.D. '56, is hosting his class
reunion this spring.
Samuel S. Kurohara,
M.D. '57, has been named a
fellow of the American College
of Radiology A native of
Hawaii, Kurohara is on the
medical staffs at several hospi
tals, including the Beverly Hos
pital in Montebello, CA, and
the LAC/USC Medical Center
in Los Angeles.
Morris Reichlin, M.D.
'59, is professor of medicine
and chief of immunology at the
University of Oklahoma. He
was a participant in a rheuma
tology symposium held in
Binningham, AL, last fall.
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Floyd E. Bloom, M.D. '60,
has been elected to the board
of the American Association
for the Advancement of Sci
ence. His four-year term begins
May 31, 1986. Bloom, director
of the division of preclinical
neuroscience and endocrinol
ogy at the Scripps Clinic and
Research Foundation in La
Jolla, CA, was the subject of
the "Silhouette" in the winter
1985 issue of Ou/wok.
Nicholas T. Kouchoukos,
M.D. '61, and Harold S.
Zarkowsky, M.D. '61, are
co-hosts of their class reunion.
Richard Marchick, M.D.
'61, is serving a three-year
term as vice-chairman of the
California Bay Area Section
of The American College of
Obstetricians and Gynecolo
gists. In private practice in
Berkeley, Marchick is on staff
at Alta Bates Hospital, where
he chaired obstetrics/gynecol
ogy and served on the medical
executive board, and at Herrick
Hospital. He is associate clini

cal professor of obstetrics and
gynecology at UCSF School of
Medicine. Formerly, he was
president of the East Bay
Gynecological Society and is a
member of several professional
organizations.
Ronald E. Rosenthal,
M.D. '61, is chief of the
trauma service in the Depart
ment of Orthopaedic Surgery
at the Long Island Jewish Med
ical Center in New Hyde Park,
New York. Rosenthal also
heads orthopedics at the
Queens Hospital Center and is
associate professor of clinical
orthopedics at the State Univer
sity of New York Health Sci
ences Center at Stony Brook.
Rosenthal, who formerly
lived in Nashville, writes that
he is looking forward to his
25th class reunion in May
John Stone, M.D. '62, has
prepared a third book of
poems, Renaming the Streets,
published by Louisiana State
University Press (Baton Rouge,
LA 70893). The book is de
scribed as " ... a work that
speaks to the future but re
mains mindful of the endless
intersection of the past and the
present. Stone writes about the
human experience in all its sea
sons: if there is suffering, pain,
loneliness, there is also love,
mercy, humor, and, always
a sense of wonder ... "
Stone, associate dean at
Emory University School of
Medicine, was profiled in the
summer 1984 issue of Ou/Wok.
Roger L. MelI, M.D. '65,
heads the council of the South
ern Medical Associations. An
orthopedic surgeon practicing
in St. Louis County, MO, Mell
trained in general surgery at
Barnes and St. Luke's hospitals
in St. Louis and in orthopedic

surgery at Barnes and allied
hospitals. Before entering med
icine, he was a pilot in the U.S.
Air Force.
Ronald K. Grady, M.D.
'66, and Jay L. Liss, M.D.
'66, are co-chairing their class
reunion this spring.
Johnny Bliznak, M.D. '67,
is a fellow of the American
College of Radiology. A native
of Texas, Bliznak is on staff at
the Hendrick Medical Center
and the Humana Hospital
Abilene (TX).
Lynn M. Taussig, M.D.
'68, is professor and head of
pediatrics at the University of
Arizona College of Medicine.
He had been acting head of that
department since last July and
associate head since 1979.
Taussig, a specialist in pedi
atric pulmonary disease, is the
principal investigator of a five
year, $1 million grant to study
children's risk factors for acute
and chronic lung diseases. His
special interest is cystic
fibrosis.
He serves on the pulmonary
diseases advisory committee of
the National Heart, Lung and
Blood Institute. He is also on

Lylm M. Taussig

the editorial boards of two
professional publications.
Formerly the vice-chairman of
the medical advisory council of
the National Cystic Fibrosis
Foundation , Taussig assisted in
the development of a pediatric
pulmonary examination for the
American Board of Pediatrics.
A 1964 cum laude graduate
of Harvard, Taussig earned his
medical degree at Washington
University. Then , he went for
further training to the University of Colorado, the National
Institutes of Health, and The
Montreal Children's Hospital.
Taussig returned to Tucson in
1974 after completing a clinical
fellowship from the National
Cystic Fibrosis Research
Foundation.
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Robert G. Harmon, M.D.
'70, is the director of the
newly-created Missouri Department of Health. Formerly,
he served as director of public
health and was health officer
for Maricopa County (AZ).
As director of the MDOH,
Harmon oversees seven district
offices. Its programs are in
environmental health and
epidemiology, health resources,
personal health services, and
local health and institutional
services.
After graduating from
Washington University School
of Medicine, Harmon earned
an M.P.H. from Jotms Hopkins
University in 1977. Boardcertified in preventive medicine, he completed a residency
in internal medicine. He is a
fellow and board member of
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the American College of Preventive Medicine. He has been
a consultant for several overseas health projects and
organizatjons.
Dixie J. Aronberg, M.D.
'71, is heading her class
reunion this spring.
Lary A. Robinson, M.D.
'72, is a fellow of the American College of Cardiology.
Currently, he is staff cardiothoracic surgeon at the University of Nebraska Medical
Center, Omaha .
Wishwa N. Kapoor, M.D.
'75, has been elected a fellow
of the American College of
Physicians. Kapoor, an internist, is on staff at PresbyterianUniversity Hospital , Pittsburgh.
Patricia Newton, M.D.
'75, psychiatrist-in-chief of
Provident Hospital, Baltimore,
was honored by Essence
Magazine for her contributions
in health and medicine. In
1983, Newton was cited by
Baltimore Magazine as one of
the city's 100 most influential
women.
In 1985, she chaired the First
Baltimore International Congress of Transcultural Psychiatry, co-sponsored by the
NIMH . Newton is assistant
professor of psychiatry at Johns
Hopkins and president of
Newton-Thoth , Inc., an international behavioral science
management consultant corporation. A member of the American Psychiatric Association
and the Black Psychiatrists of
America, she is a frequent
media spokesperson on healthrelated matters.
After completing her undergraduate work at University of
Arkansas (Pine Bluff), she
earned a master's degree from
Vanderbilt University

Peabody College. She completed a residency in psychiatry
at Washington University following graduation from medical school there. She earned an
MPH in Mental Health Administration from Jotms Hopkins
School of Public Health and
Hygiene. Board-certified in
psychiatry, she is a diplomate
of the American Board of Psychiatry and Neurology. Newton
also has certification in admjnistrative psychiatry from the
American Psychiatric
Association.
Kenneth S. Rotskoff,
D.D.S., M;D. '75, moderated
the Symposium on Nutrition
for the Oral and Maxillofacial
Surgeon at a meeting in Washington, nc. , last fall. He also
presented abstracts of his work
on surgical orthodontic
patients.
Robert L. Lamberg, M.D.
'76, has been selected to serve
on the Executive Council of the
Medical Center Alumni Asso
ciation . A St. Louis ophthal
mologist, Lamberg is clinical
instructor of ophthalmology at
the School of Medicine. He
also chairs the Medical Century ClUb, an organization of
medical alumni who are university donors. Lamberg also
serves as reunion chairman for
his class.
Keith H. Bridwell, M.D.
'77, assistant professor of
orthopedic surgery at Washington University School of Medicine, chose "Surgical Treatment of Spine Burst Fractures"
as the subject of an audiotape
he made for a national organization for continuing medical
education. He also has completed a book chapter on the
upper thoracic spine and has

co-authored a paper on compli
cations of spinal instrumentation. His work was featured in
the winter 1985 issue of
OU/look.
Pamela Freeman, M.D.
'77, FHS, is a rheumatologist
in practice in Orlando, FL.
Charles O. Hershey, M.D.
'77, is a fellow of the American
College of Physicians. An internist , Hershey is on staff
at Cleveland Metropolitan
General Hospital.
Cecil J. Holliman, M.D.
'79, has been accepted as a
member of the Berks County
Medical Society (PA). He prac
tices emergency medicine at
Community General Hospital.
Carol Mitchell Simmons,
M.D. '79, has begun a resi
dency in family medicine at the
Mayo Graduate School of
Medicine, Rochester, MN.
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David A. McLain, FHS
'75-9 and former faculty ' 79
81, is chief of rheumatology at
Brookwood Medical Center in
Birmingham, AL. He was
course director for the third
annual Brookwood Rheumatol
ogy Symposium. Speakers inc1uded C. Conrad Johnston ,
FHS '56-7, director of the divi
sion of endocrinology and
metabolism, Indiana University
Medical Center. Thomas
Traylor, FHS '75-8, was on the
program committee; he is a
Birmingham rheumatologist.
Harry Burack, FHS in
gastroenterology, recently
opened a private practice in
St. Peters, Mo.
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Keith LaFerriere, FHS,
has been named clinical assis
tant professor, Department
of Surgery, divi sion of oto
laryngology, at University of
Missouri School of Medicine
(Columbia). A member of
Head and Neck SurgicaJ Asso
ciates of Springfield Ltd. ,
LaFerriere previously served
as research associate at Kresge
Hearing Research Institute and
instructor of otolaryngology at
Washington University School
of Medicine. A fellow of the
American College of Surgeons
and the American Academy of
Facial Plastic and Reconstruc
tive Surgery, he is president
of the Missouri Society of
Otolaryngology - Head and
Neck Surgery.

Keith LaFerriere
Ramon Iglesias, FHS,
practices obstetrics and
gynecology in Coral Gables,
FL. An article about him in
the Miami Herald describes his
advocacy of sports, especially
for women.
Harold H. Sandstead,
FHS, is professor and chair
man of the Department of
Preventive Medicine and Com

munity Health at the University
of Texas Medical Branch,
Galveston . A noted researcher
in human nutrition, Sandstead
previously served as professor
of nutrition at Tufts University
and senior scientist and direc
tor of the USDA agricultural
research service. He received
the M.D. from Vanderbilt in
1959, then completed residency
in internal medicine at Barnes
Hospital and at Vanderbilt Uni
versity Hospital. His world
wide scientific reputation is in
the field of trace mineraJ
metabolism , particularly zinc.

II
Lawrence E. Acker is ad
ministrator of the MEDICAL
Rehabilitation Center of St.
Louis, a comprehensive out
patient rehabilitation facility.
A 1979 graduate of HAp, he
formerly was associate admin
istrator at St. Louis County
Hospital.
Jeffrey M. Fried has been
named vice president of opera
tions at Lancaster General Ser
vices Corp., PA. Formerly, he
was assistant vice president of
Sinai Hospital, Baltimore.
Dana S. Hensley is assis
tant vice president at Baptist
Medical Center, Montclar, AL.
Hensley is a Ph.D. candidate
in religion at Vanderbilt
University.
Mark S. Wiener joined
Research Medical Center
(Kansas City, MO) as vice
president of clinical services.
Previously, he was assistant
hospital director at University
of Nebraska Hospital and
Clinic in Omaha .

1932
Orville R. Clark, M.D.
October 7, 1985

1934
Howard R. Little, M.D.
July 21, 1985

1935
Harry Agress, M.D.
January 15, 1986

1936
Lawrence Breslow, M.D.
January 1986

1940
Mark S. Wiener
Ned Wilford was inter
viewed in the November 1985
issue of Referee. Wilford, who
earned the master's degree in
HAP in 1966 and is president
of Holmes Regional Medical
Center in Florida , is also a
Southeastern Conference foot
ball official.
His interest in sports dates
back to his high school days:
He played on a team ranked
number one in his home state,
Arkansas, when he was a
senior.

William M. Tomlinson, M.D.
February 3, 1986

1943
Jean M. Modert, M.D.
August 31, 1985
Nathaniel D. Ewing, M.D.
1985
FORMER HOUSE STAFF
Charles D. Phelps, M.D., FHS,
September 13, 1985
Harry Wilkins, M.D., FHS,
February 14, 1985

I
1923
Quince B. Coray, M.D.
October 18, 1985

1926
Clinton K . Higgins, M.D.
February 3, 1986

Medical Center Alumni
Association
Box 8049
660 S. Eucl id
St. Louis, MO 63110

1927

Nicholas T. Kouchoukos, M.D. '61

Charles H. Leslie, M. D.
June 18, 1985

PresidenJ

1931
Delevan Calkins, M.D.
July 28, 1985

Jack Siefkas, Director
Medical Alumni and Development
Programs
Kellie Semler, Director
Medical Alumni Programs
Ruth Moenster

Secretary
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nsurance charts have no category for
physicians who fly jet airplanes. But
Thomas E Frist, Jr. , M.D. '65, is an
experienced jet pilot who has flown on busi
ness all around the country. And conven
tional wisdom has it that medicine and busi
ness don't mix. But Frist , chairman and
C.E.o. of the Hospital Corporation of
America (HCA), has mixed medicine and
business skillfully enough to earn a piece
of corporate history.
"I have had a burning, compulsive,
almost obsessive desire to prove that it's not
inconsistent for a physician to be a capable
manager," says Frist. The Nashville-based
company, which he helped found in 1968
- three years after graduating from Wash
ington University School of Medicine 
has also defied skeptics: It has rapidly
grown into the largest hospital management
chain in the U.S. In 45 states and seven
foreign countries, HCA currently owns or
operates 438 health care facilities. Reaching
into related fields, it has also acquired an
ambulance subsidiary, a nursing home com
pany and a medical equipment leasing firm.
In 1986, HCA will garner $5 billion in reve
nues and employ more than 80,000 people.
Frist, a soft-spoken man with an easy
southern drawl, continues to act aggres
sively and seize the unexpected . Last year,
he surprised Wall Street by forging a giant
alliance between HCA and American Hos
pital Supply Corp., the nation's largest dis
tributor of hospital supplies. The merger
fell apart , but HCA emerged with $150
million, which Frist will turn to fresh
advantage.
"The most recent strategy of HCA, "
discloses Frist, "is to develop the national
provider network to serve the insurance in
dustry and corporate America. We will do
that through owned, managed and affiliated
hospitals, both in communities where we
are now and by filling gaps over the next
two years in the few areas where we do not
have a network."
This major new thrust for HCA , Frist
hints, will mean several joint ventures
within the insurance industry. It will also
require state-of-the-art computer and com
munication systems to link hospital , physi
cian's office, workplace and insurance com
pany. Aided by increasingly close ties with
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"Goingfrom a cost-plus payment system to a competitive, market-driven system has
chmlged the course ofmedicine," says Thomas Frist, founder ofHospital Corporation of
America (HCA). (photo courtesy ofHCA)
local physicians, "we will build the system
of the future, " he says.
Growing up in a family full of physi
cians, Frist learned early about health care.
His father, Thomas E Frist, Sr. , was a lead
ing Nashville cardiologist and an associate
professor of medicine at Vanderbilt's School
of Medicine. One brother became a cardiac
surgeon; a second joined the heart trans
plant program at Stanford. Cousin John
Frist , M.D. '66, went on to practice plastic
surgery in Nashville.
From childhood , Frist had his sights
set on surgery. After undergraduate training
at Vanderbilt , he decided to broaden his
experience and was drawn to Washington
University by its strong reputation. Imme
diately, he was impressed by the spirit of
cooperation between professors, house staff
and medical students.
"The professors not only took pride in

research, they also enjoyed teaching. This
combination created an exciting climate for
medical students. You saw that with Dr.
Carl Moore of the Department of Medicine,
Dr. Carl Moyer of surgery, and Dr. [Lauren]
Ackerman in pathology. They were there,
participating in rounds ; they made medical
students feel as if they were part of a team .
In business, we call that a ' corporate cul
ture.' Washington University has a unique
'culture' for a medical center and should be
the envy of all others," he says.
Returning to Vanderbilt, Frist completed
his surgical internship and was beginning
his residency when he was drafted to serve
as an Air Force flight surgeon during the
Vietnam War. That stint gave him time to
ponder a lesson he'd learned from a college
fraternity brother, son of a Holiday Inn
founder : "Holiday Inns of America created
the motel business," muses Frist. " Until that
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time, travellers had two choices - boarding
houses or uptown hotels. I realized that
there were 7,000 independently-operated
hospitals being run as a cottage industry.
The same opportunity existed there as in
the hotel industry."
Discharged from the service and three
months away from returning to his resi
dency, Frist went to Vanderbilt's head of
surgery with two decisions: He was not re
turning to complete his training, and he was
going to start a for-profit hospital company.
"You can imagine what the reaction was,"
Frist says wryly. "I was concerned too.
I knew there was tremendous potential, but
there was also a great deal of risk."
From the start, Frist had high-powered
help from co-founders Jack C. Massey,
whose business acumen derived from his
roots in Kentucky Fried Chicken; and from
the senior Frist, whose own Parkview Hos
pital (acquired during the 1950s) formed
the nucleus of the fledgling HCA. After
only 18 months, the new firm had II hospi
tals; soon, HCA developed its lasting pat
tern of doubling in size every three years.
At first , Frist concentrated on acquisition
and development. "That was where I was
able to use my background in medicine, my
love of business, and my hobby of aviation,"
he says. "I put all three together and went
personally to visit communities, meet
doctors and see hospitals."
Frist targeted the southeast US., then
experiencing tremendous growth. Capital
starved communities were scrambling to
finance new schools or public utilities; they
lacked money to improve outdated hospi
tals. "We were not necessarily the first or
even the second choice," Frist says. "If the
local government or religious order could
not fulfill the need, we were often - at
least in the early years - the answer of last
resort. Gradually, we built a track record
which allowed us to take on larger and more
prestigious projects."
After five years in business, HCA no
longer limited itself to eligible proprietary
hospitals; communities began selling the
firm their not-for-profit hospitals. A few
years later, hospitals were seeking out HCA
to manage their tax-exempt facilities. Today,
approximately half HCA's hospitals are tax
able; the rest are tax-exempt.

"But in 17 years, those artificial designa
tions have blurred, just as they have in the
financial world," reflects Frist. "It is diffi
cult today to tell a bank from a savings and
loan from an investment banking house.
Likewise, you have the traditional not-for
profit hospital with for-profit subsidiaries
and for-profit hospitals with not-for-profit
subsidiaries. "
The scope of HCA's business has also
changed. No longer simply a hospital chain,
it has become a fully integrated health care
system that provides wide-ranging care:
in-patient, out-patient, home health, long
term and psychiatric,
And like HCA, the entire US. health
care system is in flux, prodded by 1983
changes in Medicare reimbursement policy.
"If that hadn't occurred, the alternatives
were not bright," Frist says. "We were
marching down the road very rapidly
toward socialized medicine - and, ulti
mately, a national health system - as a re
sult of uncontrolled, double-digit inflation.
This bold, dramatic change - going from
a cost-plus payment system to a competi
tive, market-driven system - has changed
the course of medicine. The system has be
come, in a relatively short time, far more
cost-effective than I could ever have .
dreamed."
That process is taking a toll, he adds.
Over the next decade, probably 400 to 500
hospitals will close. Others, including uni
versity medical centers, will join hospital
groups to create new kinds of affiliations
- joint ventures, management contracts,
equity investment, and outreach programs
that stretch beyond their geographical
boundaries.
HCA will playa central role in these new
developments. Already, Frist says, the firm
has made an important difference to the
quality of American health care. In commu
nities where HCA has built or acquired a
hospital, he contends, the patients are now
receiving better health care; in communities
where an HCA hospital exists alongside
others, its presence has given its com
petitors the incentive to improve.
Frist is starting to look ahead to the end
of his leadership of HCA. Named president
in 1978, he learned the skills of manage
ment from Donald S. MacNaughton, former

C.E.o. of Prudential Insurance who joined
HCA as chairman in 1979. Frist became
C.E.O. in 1982 and chairman last Sep
tember: "My feeling is that a person can be
effective as C.E.O. of a major company for
a maximum of eight to ten years," he says.
Within five to six years, he may consider
moving on to other opportunities in health
yare, leaving his company" . .. in an emi
nent position, where it will have a bright
future. "
To harness the energy for the corning
critical years, Frist relies on exercise. A de
voted jogger who frequently runs during
airport stopovers, he has completed 16
marathons. He balances his other respon
sibilities, which include national-level work
for the United Way, with a strong commit
ment to his family: wife and former child
hood sweetheart Patricia Gail Champion ,
and three children.
Although he has never practiced medi
cine, Frist is grateful for his medical train
ing. It was useful through HCA's early
years, facilitating his communication with
physicians. But during HCA's growth spurt,
it occasionally hindered him; he had to
prove his mettle as a Fortune 500 company
executive. With the nation's sharpened
focus on health care delivery systems, how
ever, his training has re-emerged as an asset
in building his - and HCA's - credibility.
He says that he will always bear fond
memories of Washington University. For
one thing, HCA continues to draw on the
Health Administration Program (HAP) at
the School of Medicine for its managerial
staff. "And I know that having attended the
medical school, with its great tradition as a
center of excellence, has provided me with
intangible benefits greater than I can mea
sure. I'm very appreciative of that."
He is also thankful for his chance to
shape a vital American industry. "I've en
joyed playing a role in the changing of
America's health care delivery system , It
has always been thought of as synonymous
with quality. Now we're demonstrating that
we can be effective managers as well."

Candace 0' Connor is a free-lance writer and
frequent contribuJor to Outlook.
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"Speaking Jor the Hearf' is t~ title of the 1985 annual report
poster issued by the Washington University Medical Cenler. This
iIlllstraliml, one oJnwre than 10 on the poster, depicts surgical
treoJmentJor coronary artery disease. In t~ prtJretlure, diseased
coTOlUUY arteries are bypassed with grqfts as shown. The pa
tient's own internal mammary arteries and veins can c1uuureIan
utUJbstructed supply of bloodto ischemic heart muscle, relieving
symptoms like angiTlll.
A limiled supply oJ"Speaking Jor the Hearf' posters is aMil
able. 10 oblLlin a copy, pkose call 314-362-8258.

